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Abstract 
Molecular imaging is a field widely used in the diagnosis and treatment of 
cancer. We offer here a modular method for the synthesis of targeted molecular imaging 
agents (TMIAs), which will improve the accuracy of current molecular imaging 
methods, as well as allow for earlier detection of tumors. The use of TMIAs in 
molecular imaging yields increased signal at cancerous cells and reduced signal from 
healthy cells. Our modular approach is useful as a facile method for the synthesis of 
dual-modal TMIAs for PET-MRI, which combine the sensitive detection of functional 
activity from PET with the high-resolution structural information obtained by MRI. 
Here, we present the synthesis of both a TMIA for the MRI of prostate cancer, followed 
by the synthesis of a dual-modal TMIA for use in simultaneous MRI-PET.  By our 
method, a lysine backbone is utilized for the synthesis of imaging modules, by means 
of coupling the DOTA cyclene to the side chain of the lysine. A metal such as Gd3+ for 
use as an MRI contrast agent is chelated by DOTA. The imaging module is then coupled 
to a targeting moiety, such as c(RGDyK), through a carbon linker such as DSS or 
SMCC, to yield a novel TMIA. This same method is applied to the synthesis of dual-
modal TMIAs featuring imaging modules for use in both MRI and PET. In the case of 
PET, where a radioactive isotope is required, we utilize a stable lanthanide placeholder 
that can be replaced by a useful metal isotope, such as 64Cu, at the end of the synthesis. 
Through the course of this research, our modular approach to the synthesis of TMIAs 
has proven to be an effective method of synthesis, and intermediate steps have been 
optimized. Additionally, methods of measuring the relaxivity of MRI contrast agents 
have been applied to our novel compounds for comparison with commercial agents 
available in clinical labs, hospitals, and imaging centers today. 
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Abbreviations 
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 Lys, K: lysine, a natural amino acid 
 NMM: n-methylmorpholine 
 TEA: triethylamine 
 TFA: tetrafluoroacetic acid 
 
Other Instrumentation 
 HPLC-MS: high-pressure liquid chromatography and mass spectrometry 
 HPLC-prep: preparative high-pressure liquid chromatography 
 NMR: nuclear magnetic resonance 
 SPE: solid-phase extraction  
 
Molecular Imaging Terms 
 CA: contrast agent for MRI use 
 MRI: magnetic resonance imaging 
 PET: positron emission tomography 
 TCA: targeted contrast agent for MRI use 
 TMIA: targeted molecular imaging agent 
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Chapter 1. Introduction 
1.1 Background: Cancer 
 Cancer is among the most widely feared diseases of the twenty-first century, 
and one of the leading causes of mortality worldwide, due to the numerous types which 
can manifest and cause damage. In 2012, more than 14 million new cancer cases 
appeared worldwide, and there were more than 8 million deaths due to cancer.1 Even 
as our medical understanding of the disease improves and developments are made in 
medical treatment of cancer, the number of new cases of cancer annually worldwide is 
expected to increase to 22 million by 2030.2  Improving methods for the detection and 
treatment of cancer are crucial areas of research to pursue in the fight against cancer. 
 Cancer begins as a localized disease based on unrestrained cell replication. Cells 
reproduce; that is the basis of life. Healthy cellular reproduction is in equilibrium with 
cellular death and decay. When there is an error in the cells’ DNA which causes the 
cells to reproduce too quickly, unrestrained reproduction results in the growth of a 
tumor, which may or may not be cancerous. Some tumors are benign: they remain 
localized to one area, generally do not increase in size beyond a certain point, and can 
easily be removed if needed, though they often don’t warrant such treatment. (Moles 
are one example of such a benign tumor.) Other tumors, however, may be malignant, 
and are considered cancerous. Cancerous cells are able to progress through the 
circulatory and lymphatic systems, leading to metastasis to other parts of the body. The 
cancer then interferes with other cells and essential biological functions, resulting in 
serious illness or death.3  
 After the cancer has metastasized and tumors are growing in different regions 
across the body, surgical treatment of the cancer becomes difficult and will likely not 
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be wholly effective, so more aggressive methods of treatment are required. These 
aggressive treatments include chemotherapy and radiotherapy, which are meant to slow 
or stop the growth of the cancerous cells that reproduce so quickly. However, these 
methods of treatment often cannot distinguish any difference between cancerous cells 
and healthy cells, so all fast-growing cells are attacked, including, most notably, hair 
cells and cells in the digestive tract, such as those in the stomach and intestines. 
Although chemotherapy and radiation are successful in a large proportion of cases, it is 
no secret that these aggressive treatments take their toll on the patients. Side effects of 
chemotherapy- and radiation-based treatments can cause problems in and of 
themselves, and include a loss of hair, loss of appetite, change in taste preferences, 
vomiting, dehydration, fatigue, lymphedema, and blood disorders such as low red blood 
cell counts.4 
1.2. Molecular Imaging in Cancer Treatment 
Because cancerous tumors can develop and spread very quickly, early diagnosis 
is the best defense against cancer. If a cancer is detected at an earlier stage, before it 
has metastasized, then the tumor(s) may be more easily removed by surgery, 
chemotherapy or targeted radiation than would be possible for a more developed form 
of that cancer. Currently, a variety of methods are used to detect and diagnose cancer 
in patients, including invasive methods (such as biopsies) and non-invasive imaging 
methods such as x-rays, computed tomography (CT), positron emission tomography 
(PET), magnetic resonance imaging (MRI), and ultrasound imaging techniques.5–8 In 
some types of molecular imaging (most notably, MRI, PET, and CT), a variety of small 
molecules, nanoparticles, quantum dots, or biosensors may be useful as imaging agents 
or contrast agents which improve the quality of the image.8–10 
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Regardless of the method of imaging used, the purpose is to allow medical 
professionals to locate the cancerous cells in the body, determine how far the cancer 
has spread, and to what degree it is currently present in the body, and determine the 
most effective method of treatment. If the cancer is diagnosed, detected, and located 
prior to metastasis, the tumors are small and localized, and can be surgically removed 
with good prognosis.  
However, such early detection is not always possible with current methods of 
imaging. At very early stages, cancerous cells may not be distinguishable from healthy 
tissue in the image. Therefore, improvements in methods for molecular imaging of 
cancer cells offers great potential to aid doctors in the early detection and treatment of 
cancer, and will reduce the mortality associated with the most fatal types of cancer. 
 When methods of molecular imaging are considered, the extent of imaging 
required for diagnosis and treatment should be limited. This is especially true in 
methods involving exposure to potentially harmful radiation or materials. Some 
methods of imaging, such as PET, rely on the use of radioactive nuclei. Other imaging 
methods use radiation in the form of short-wave energy, such as x-rays and CT scans, 
and while limited exposure (for example, that which is experienced during the 
acquisition of a single x-ray image) is safe for the average patient, repeated exposure to 
ionizing radiation can be detrimental, and may itself may be a factor which contributes 
to an increased risk of cancer.11 Additionally, the risks associated with such radiation 
exposure are elevated for patients of compromised health, such as young children, those 
already suffering from chronic ailments, and the elderly. 
 When all of this is taken into account, there are several important factors to keep 
in mind when considering methods for the improvement of molecular imaging methods 
and the application of such methods to the diagnosis and treatment of cancer. One: the 
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imaging method should be specific to the cancerous cells of interest, so that even small 
areas of cancerous cells may be distinguished from healthy tissues, and so that healthy 
tissues will not be misdiagnosed as tumors. Two: the efficiency of the contrast agent 
used for the imaging method should be increased, thereby lowering the required dosage. 
This will reduce the potential for negative side effects that result from the accumulation 
of toxic metals in the body or excessive exposure to radiation. Three: the improvements 
to imaging methods should be easily translated to the diagnosis and treatment of a 
variety of cancers, in order to have the widest possible impact.  
1.3 Targeted Molecular Imaging Agents  
One recent development towards improving molecular imaging methods is the 
use of targeted molecular imaging agents (TMIAs).7,12–14 By targeting the imaging 
agent to the cancerous cells, the imaging agent will collect more densely at the diseased 
areas of tissue. This increases the signal at the diseased cells and reduces the signal 
arising from healthy cells.15 Therefore, the cancerous cells can be more easily 
distinguished from the healthy tissue, even when only very small quantities of diseased 
cells are present, and the cancer can be more effectively treated and removed from the 
body. Biomarkers on cancer cells have been successfully targeted in a number of 
molecular imaging methods, including ultrasound imaging, near infrared (NIR) 
imaging, MRI, and PET, by coupling a compound or small protein with an affinity for 
a biomarker to a contrast or imaging agent.7,12,14,16,17 
 Potential biomarkers for cancerous cells include a variety of components.  For 
example, prostate cancer tumors and cells overexpress prostate-membrane specific 
antigen (PSMA), so PSMA can function as a target for cancer treatments and imaging 
methods for use in patients with prostate cancer.17–19 Tumors found in breast cancer, on 
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the other hand, overexpress estrogen receptors (ER), progesterone receptors (PrG), and 
human epidermal growth factor 2 (HER2), each of which may serve as a targeted 
biomarker in breast cancer imaging, as shown in confocal fluorescence microscopy 
(CFM) studies.5  
 
1.4 Targeting Groups of Interest 
In the early days of molecular imaging, certain peptides were found to target 
biomarkers found on a wide range of cancerous cells, such as cyclo(Arg-Gly-Asp-dTyr-
Lys), or c(RGDyK) (Figure 1). The RGD peptide has an affinity for the αvβ3 integrin 
that is overexpressed in a number of types of cancer cells, including melanoma, ovarian, 
lung, and breast cancer.20,21 c(RGDyK) is favored as a targeting group and is used to 
test targeted imaging methods due to its reproducible affinity for a variety of cancer 
cells. 
 
Figure 1. c(RDGyK) 
 
The cyclic peptide, c(RGDyK) was also the first targeting moiety employed in 
our imaging agent lab leading to early TMIAs in our group in which the dye Cy5.5 was 
simply bound to the targeting agent, and was utilized to provide CFM images of A549 
lung cancer cells in the Evans lab here at RIT (Figure 2). 
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In the interest of creating TMIAs which are useful for specific types of cancer, 
it is important to explore specific targeting groups which might be useful for biomarkers 
of different cancers. Within our group, we have developed a method for the synthesis 
of a urea-based targeting moiety for prostate cancer (PrCa). DCL urea (Figure 3) is 
based on the Glu-urea-Lys dipeptide, and is known to target PSMA and therefore is 
being aggressively pursued in clinical studies as a targeting group in PrCa-specific 
imaging agents or treatments.22–29 Based on this current research, DCL is a strong 
candidate for use in a contrast agent that is specific to PrCa.  
 
 
 
Figure 3. DCL urea-based PSMA inhibitor. N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-L-lysine. 
 
Targeting Peptide
   c(RGDyK)
NIRF imaging 
dye Cy 5.5
Figure 2. CFM images of A549 lung cancer cells targeted by NIR-TMIA: c(RDGyK)- Cy5.5 
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There are also more specific targeting moieties being developed, including a 
targeting peptide for breast cancer (BrCa), 18-4 (WxEAAYQkFL). Dr. Kamalijit Kaur 
(Chapman University, CA) developed that peptide and is collaborating with our group 
to synthesize a TMIA for BrCa.30 The variety of targeting moieties available for use 
demonstrate the opportunities for collaboration and broad range of impact for this field 
of research.  The peptide, shown in Figure 4, has been synthesized in our lab and is the 
focus of a related TMIA project.   
 
Figure 4. Structure of Breast cancer peptide 18-4. 
   
1.5 Molecular Imaging Methods 
 In addition to targeting the cancer cells, the method of imaging used must be 
considered in the future of cancer diagnosis. Each imaging method – PET, MRI, 
photoacoustic (PAI), CFM, and others, offers its own merits and suffers its own 
shortcomings.  For example, CFM produces a very sharp three-dimensional image, but 
the depth of the image below the surface of the sample is limited to about 100µM, which 
limits this technique to in-vitro imaging.  
To counter the shortcomings associated with each method of imaging, dual-
modal (sometimes also called bi-modal) molecular imaging has gained some ground in 
recent years.31,32 Dual-modal imaging involves the combination of two imaging 
techniques; the images may be obtained simultaneously using specialized 
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instrumentation, or the images may be digitally fused in the post-processing stages. The 
imaging techniques for dual-modal methods are selected to complement each other – 
that is, it wouldn’t be overly helpful to combine two methods of imaging which both 
provide structural information, but combining structural details with mapped biological 
activity would very practically applicable. In the field of cancer imaging, simultaneous 
PET/MRI is presented as a dual-modal method of choice, and will be further explored 
below.17,33,34 
 PET provides physiological data for a variety of biological functions, such as 
blood flow, oxygen use, and sugar metabolism.35 Although PET is sensitive to the 
presence of even very small amounts of radiotracer in a sample, this method does not 
provide significant structural resolution for the sample. It is not immediately clear from 
a PET scan which tissues are present or whether the anatomy is at all abnormal.  
 Therefore, it is useful to fuse PET images with structural information, such as 
images obtained by CT or MRI, for a more complete analysis of cancerous cells present 
within the patient. An example of such an image overlay is shown in Figure 5. Structural 
tissue information from MRI is compared to physiological data from PET to provide a 
more specific, more accurate diagnostic of smaller cancerous tumors. 
 
Figure 5. An example of individual PET and MRI scans, and the fused image of the two scans, showing 
the high-resolution structure and the sensitive biological activity information which can be obtained 
from such an image.36 
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The integration of PET with either CT or MRI can be done with in-line systems 
(which produce both images simultaneously) or by obtaining the images from two 
separate instruments and fusing the images in post-processing. However, if images are 
to be fused during post-processing, it is important for the images to be properly aligned, 
so that the signal in the final image is correctly mapped to the body. Improper alignment 
can result in a number of problems, including misled assignment of surrounding tissues 
or incorrect diagnosis regarding the size of the tumors. If the images are overlaid 
accurately, however, they can be most useful to the diagnostic team. Therefore, 
validated methods for the accurate overlay of MRI and PET images are essential for 
diagnostic techniques associated with dual-modal imaging.37    
 PET/CT imaging methods are commonplace in hospitals today after an in-line 
method for simultaneous bi-modal imaging was introduced in the late 1990s.38 Today, 
the use of PET/MRI is considered a potential competitor for PET/CT, because MRI 
provides a comparable structural resolution when compared to the data obtained by CT, 
and because MRI does not involve high-energy x-ray exposure.39–41 PET/MRI has also 
been shown to offer higher diagnostic accuracy when directly compared to PET/CT.34 
 The primary factor currently preventing a complete transition from CT to MRI 
is a financial one. PET/CT and PET/MRI provide comparable results at the moment, so 
it is difficult to justify the expensive change from one to the other. However, MRI has 
been shown to be more sensitive than CT in some situations, such as soft tissue imaging, 
and further research and improvements to PET/MRI systems may encourage such a 
switch.42,43 
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1.6 Magnetic Resonance Imaging 
1.6.1 A Simple Treatment of MRI Theory 
 MRI is a non-invasive method of molecular imaging which uses magnetic fields 
to manipulate nuclei that have a magnetic spin.44 These nuclei include 1H, 2H, 13C, and 
14N, among others. During an MRI scan, a strong (1.5 to 3 Tesla) magnetic field (B0) is 
applied along the designated z-axis, which aligns the nuclear spins to be parallel with 
that B0 field. An RF pulse rotates the nuclei 90 degrees into the xy-plane, perpendicular 
to B0. While the nuclei are in this position, there is net transverse magnetization within 
the sample, and the nuclei precess at their Larmor frequencies as determined by the 
chemical environment; this is related to the familiar chemical shift observed in NMR 
spectra (Figure 6). The precession and the transverse magnetization induce a current in 
an RF coil. This induced current is recorded as a signal in the image. However, because 
a large magnetic field is still in place, the nuclei will eventually return to their thermal 
equilibrium and realign with the B0 field, at which point the induced current in the RF 
coil decays and, with it, the signal. 
 
 
Figure 6. Representation of the precession of a nucleus about the applied B0 magnetic field..45 
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The process by which the nuclei return to their thermal equilibrium positions is 
known as relaxation. There are two different relaxation processes to consider in MRI: 
T1 and T2. Both of these affect the strength of the signal produced in the image. The 
longitudinal relaxation time (T1) is a measure of how quickly a nucleus returns to its 
equilibrium alignment with B0 after the application of an RF pulse, which rotates the 
nuclei spins by 90 degrees. The spin-spin relaxation (T2) is the process by which the 
net transverse magnetization decays to zero, which occurs because not all spins within 
the sample precess at exactly the same frequency, but are, rather, slightly out of phase, 
so after many precessions, the spins will ‘cancel’ in the transverse direction and the net 
transverse magnetization will eventually be zero (Figure 7).  
 
 
Figure 7. Representation of the T2 decay process, showing how the many spins in a sample dephase 
over time after the initial excitation by an RF pulse to ultimately produce a net magnetic spin of zero. 
 
Those relaxation processes, T1 and T2, are measured according to the time it 
takes the signal from a sample to decay by a factor of e, and are affected not only by 
the tissues present in the sample, but also by the parameters used for the acquisition of 
the image (which are beyond the scope of this background discussion). T1 and T2 can 
then be considered as rates by taking the reciprocal of the relaxation time for each 
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process. The longitudinal relaxation rate, R1, is 1/T1, and the spin-spin relaxation rate, 
R2, is 1/T2.  
 
1.6.2 MRI Contrast Agents 
In the field of MRI, contrast agents (CAs) are commonly used to increase the 
signal generated by different types of tissues. There are two general classes of CAs for 
MRI: ferromagnetic and paramagnetic. Ferromagnetic CAs distort the magnetic field 
surrounding the CA, which have the primary effect of shortening the T2 time for nearby 
nuclei. Common ferromagnetic (or T2) CAs are based on iron nanoparticles. 
Paramagnetic (or T1) CAs, on the other hand, have unpaired electrons which primarily 
increase the rate of T1 relaxation of the nuclei in the surrounding tissue.  
Gadolinium (III) is the most frequently used paramagnetic CA due to its seven 
unpaired electrons (for a total electron spin of 7/2). CAs are considered in terms of their 
relaxivity, which is the extent to which a specific CA affects the relaxation rate of the 
tissues per unit concentration of CA, per equation (1), where n = 1 or n = 2, depending 
on which relaxation mechanism is being investigated, rn is the relaxivity of the CA, Tn 
is the relaxation time for the nuclei of interest when a certain concentration of CA is 
present in a treated sample, T0 is the relaxation time for the untreated sample when no 
CA is present, and [CA] is the concentration of CA present in the treated sample. The 
relaxivity rn has units of s
-1mM-1. 
𝑟𝑛 = (
1
𝑇𝑛
−
1
𝑇𝑛0
) ÷ [CA]   (1) 
The DOTA chelating group and other cyclenes are frequently used for both MRI 
and radioisotope imaging methods (such as PET).46 Many metals used in imaging, such 
as Gd(III), are safe when chelated but can have problematic effects on the body if they 
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are released from the chelating group.47 For example, Gd(III) has a similar size to 
Ca(II), and therefore competes with Ca(II) in biological processes.48  
It is therefore necessary to develop highly stable complexes to protect the body 
from the Gd to be used during imaging. DOTA-metal complexes have been shown to 
be kinetically stable, and Gd-DOTA is particularly kinetically stable, so DOTA-type 
complexes are favored for MRI contrast agents, and are available as commercial CAs 
(Figure 8).31 In the end, a kinetically stable targeted MRI contrast agent with a high 
relaxivity could be used in much smaller doses, and the amount of gadolinium which a 
patient is exposed to would be cut drastically while still providing useful results to their 
treatment team.  
 
 
Figure 8. A selection of commercially available Gd-based CAs.49 
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1.7 Positron Emission Tomography 
1.7.1 Theory and Physics of PET 
 PET is based on the use of radioisotopes which will undergo the process of 
positron decay, also known as beta plus (β+) decay.50 Unlike MRI, which can be done 
without a contrast agent, PET is not possible without the introduction of a suitable 
radioisotope into the sample. Commonly used radioisotopes for PET include 15O, 18F, 
11C, and 13N, because it is easy to incorporate them into organic molecules that are 
metabolized by the body and, by that process, track the metabolic processes in a region 
of interest. 
 During the process of positron decay, a proton within the unstable nucleus is 
converted into a neutron, and a positron, bearing the mass of an electron and the positive 
charge of a proton, is emitted.51 The energy of the positron will vary depending on what 
type of nuclei has decayed: a positron from 18F decay will most often have around 
200keV of energy (and a maximum of 630keV), while a positron from 68Ga positron-
decay has roughly three times that. The positron will travel some small distance, on the 
scale of millimeters, while it loses kinetic energy – in 18F decay, this is an average of 
0.6mm, with a maximum of 2.4mm; for 68Ga, an average of 2.9mm and a maximum of 
8.2mm. When the positron has approximately come to rest, it undergoes annihilation 
with an electron, and this annihilation releases two photons with 511keV at 180 degrees 
from each other, whose locations can be recorded by detectors within the instrument 
(Figure 9). 
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Figure 9. Elementary graphic explanation of theory behind PET.52 
 
1.7.2 Radionuclide Imaging Agents 
 18F has been commonly used as a radionuclide for PET in the form of 18F-fluoro-
2-deoxy-glucose (18F-FDG). In this form, it is particularly useful for cancer imaging, 
because the similarities to glucose cause the imaging agent to accumulate in cancerous 
tumors more so than in healthy tissue.53 However, there are a number of issues to deal 
with when using 18F-FDG, including difficulties during the synthesis of the 
radionuclide and the short lifespan of the radioisotope.   
Because of this shortcoming, 64Cu has gained attention within the last 30 years 
for use as a radionuclide for PET.54 Copper has a number of radioactive forms, each of 
which has a different half-life and produces positrons with different amounts of energy. 
64Cu has a half-life of about 12.7 hours, which is significantly longer than several 
radioisotopes that have been used for PET in the past, including 15O, 18F, 11C, or 13N, 
which have half-lives on the scale of minutes (Table 1). This characteristic makes 64Cu 
a more useful candidate for imaging biological processes which make take longer to 
occur, and, when coupled with a targeting moiety, will provide more time for the 
imaging agent to accumulate at the desired area.  
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Additionally, the coordination chemistry of 64Cu is well understood and can be 
taken advantage of to produce an imaging agent that is stable in vivo. Although 64Cu 
undergoes multiple types of radiodecay and not all are useful for PET, this is less of a 
problem than it might first seem to be, due to the sensitivity of PET. Also note that 68Ga 
is also often used as a nucleus for PET, despite the fact that it decays by positron 
emission less than 10% of the time. 
 
Isotope Half-life β+ energy Odds of β+ 
decay 
C-11 20.4 min 0.385 MeV 99.8% 
N-13 9.97 min 0.492 MeV 100% 
O-15 122 seconds 0.735 MeV 100% 
F-18 110 min 0.250 MeV 100% 
Cu-64 12.7 hours 0.278 MeV 17.9% 
Ga-68 68.1 hours 0.836 MeV 8.79% 
Table 1. Summarizing some useful properties of isotopes used in PET as radionuclides for imaging.55 
 
It is important to ensure that the 64Cu is securely held in place in the TMIA 
before it is exposed to any in vivo conditions. While copper is an essential nutrient for 
humans, it is still possible for too much copper to accumulate in the body and interfere 
with certain biological processes. Particularly when a radioactive form of copper is 
being used, it is most undesirable to allow the radioactive copper to accumulate in any 
part of the body. Additionally, if the copper is removed from the chelating group in the 
TMIA, the imaging agent is no longer effective for PET. DOTA and DOTA-type 
derivatives are frequently used as chelating groups, and Cu2+ chelates of DOTA and its 
derivatives have been shown to be kinetically stable at in vivo conditions for 
radiopharmaceutical work.56  
17 
 
 
Because we do not have access to radioactive metals, we utilized the cold 
isotopes of each respective metal in our studies – that is, we used the stable 63Cu2+ and 
65Cu2+ in our studies, rather than the radioactive isotope 64Cu. However, because the 
size of the metals will not be greatly affected by that difference, the stability of the 
product and relative reaction rates are expected to be the same for both the cold and 
radioactive isotopes. 
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Chapter 2. Experimental Approach 
2.1 Modular Synthetic Approach to TMIA Synthesis 
Our group is interested in a peptide-based modular approach to synthesizing 
imaging agents. Imaging or contrast modules for each imaging method are synthesized, 
and the relevant imaging and targeting modules are coupled together.57  An amino acid 
backbone such as lysine is favorable due to its primary amine side chain. This functional 
group is easily coupled to a chelating group (such as DOTA) for chelation of a metal 
that is useful for imaging. Peptides are preferable over original small molecules that 
could possibly be designed. They have known advantages in medicinal chemistry due 
to their relatively small, compact structures and their bioavailability and biostability.58 
Because the reagents and coupling mechanisms for peptides are fairly well known, we 
can focus efforts on developing new TMIAs, rather than developing new reactions.  
Ultimately, the goal of this work was to prove the usefulness of our modular 
method by its application to the synthesis of two unique TMIAs: one for MR imaging 
of prostate cancer, and one for simultaneous MRI and PET of cancerous cells 
overexpressing the αvβ3 integrin.  
 Our method involves synthesizing each module of the TMIA on a lysine 
backbone before constructing the TMIA from C terminus to N terminus, as is the norm 
for peptide synthesis. In this case, for the synthesis of a TMIA for PET/MRI of some 
cancer, the synthesis proceeds generically as shown in Figure 10. Each of the modular 
components (MRI contrast module, PET imaging module with placeholder, linker, and 
targeting moiety) are either synthesized and purified in-house, or purchased from a 
commercial source, and then coupled to yield the penultimate product in the synthesis. 
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The last step is a simple transmetallation to replace the La2+ with Cu2+, where the use 
of Cu2+ in our lab functions as a substitute for a radioactive metal.  
 
Gd-DOTA
Gd-DOTA
La-DOTA
La-DOTA
Targeting 
Moiety
Targeting 
Moiety
Linker
Linker
(such as DSS 
or SMCC)
(such as c(RGDyK) 
or DCL for PrCa)
(PET imaging module 
with La placeholder to be 
transmetallated after coupling)
(MRI contrast module)
 
 
 
 
 
Figure 10. General schematic for synthesis of a dual-modal TMIA 
Figure 11. Color-coded structure for one of the final TMIA products,  
c(RGDyK)-SMCC-dK(DOTA-Cu)-K(DOTA-Gd)-NH2, useful for targeted PET-MR of cancer. 
20 
 
 
A specific TMIA for use in dual-model MRI/PET of cancer is shown above 
(Figure 11). This particular TMIA features the MRI contrast module in purple 
(Lys(DOTA-Gd)-NH2), the PET imaging module in blue (dLys(DOTA-Cu)-OH), a 
carbon linker in black (SMCC), and a commercially-available targeting group in pink 
(c(RGDyK)).  
In the world of peptide synthesis, there are important choices to make regarding 
the methods available. These include convergent versus linear synthesis, and solution-
phase versus solid-phase synthesis. Linear and convergent methods of synthesis refer 
to the order in which the peptide is built. In a linear method, the peptide is built from 
right to left. The components are connected by building peptide bonds, which involve 
a terminal N on the first component and a terminal C on the second (from right to left). 
For a specific dual-modal TMIA of interest, the linear synthesis would proceed 
according to Scheme 1. In a convergent method of synthesis, the synthesis follows 
Scheme 2. Traditionally, our group has focused on a linear method when building the 
final peptide-based TMIAs, but convergent methods have provided better yields in 
certain cases. 
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Scheme 1. Schematic for linear method of dual-modal TMIA synthesis. 
Scheme 2. Schematic for convergent method of synthesis for dual-modal TMIA. 
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The decision to use solution-phase peptide synthesis methods rather than solid-
phase methods was made based on a number of factors. Solution-phase synthesis tends 
to be more useful for shorter peptides, and the dual-model imaging agent modalities of 
interest involve just two lysine groups. Additionally, solid-phase methods require a 
linear synthesis of the final product. Solid-phase methods also require a specific type 
of resin for the peptide synthesis, which can become costly, and increases the number 
of factors that must be considered during synthesis, whereas solution-phase synthesis 
requires only a suitable organic solvent as a medium.  
Solid-phase synthesis is often preferred because the intermediate products do 
not need to be removed from the resin and purified; rather, the final peptide is cleaved 
from the resin only after synthesis is complete. In this situation, that feature is not 
necessarily a benefit, because we want to focus on the modality of the synthesis, and 
how simple it can be to substitute in a different imaging contrast agent or targeting 
group during the procedure. For example, we can potentially synthesize a dual-modal 
imaging agent and linker (DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2) in large quantities, 
and later couple a small sample of this compound to different targeting groups. 
 
2.2 Novel use of Metals as DOTA-Protecting Groups 
Imaging and contrast agents have been in use since the eighties – altogether, a 
relatively new field of science. But the idea of targeting the imaging or contrast agents 
to a specific type of cell is newer still. The synthesis of such agents, then, is a developing 
area of chemistry. Even so, there are already somewhat ‘standardized’ methods of 
synthesis for targeted molecular imaging agents. 
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Because a metal is required for imaging methods such as MRI and a radioactive 
isotope is required for PET, the addition of a metal to the compound and its chelation 
into a group such as DOTA is a very important step. Current methods in the literature 
generally consider chelation as the last step in the synthesis of an imaging agent. Our 
group, however, has developed a different procedure, in which the metal is chelated 
into the DOTA-type macrocycle in the early stages of synthesis.  
By chelating the metal early on in the synthesis, the metal itself functions to 
protect the chelating group from undesirable side-ructions: DOTA and similar chelating 
groups contain reactive functional groups (i.e., carboxylic acids and amines). Left 
unprotected, these groups are susceptible to further reactions during the synthesis. Most 
methods in the literature rely on protecting groups such as t-butyl groups to protect 
these carboxylic acids; the protecting group is removed in the latter stages of synthesis 
by treatment with a strong acid like TFA before the metal is chelated. This modular 
method avoids harsh deprotections and the associated risk of decomposition of the 
TMIA under those conditions. We have found that the metal is just as capable as 
traditional protecting groups of shielding the DOTA group from further chemistry 
during synthesis. 
Chelating a metal at the beginning of the synthesis is easily said, and for stable 
isotopes (i.e. 157Gd3+ for MRI) it is easily done. However, PET requires a radioactive 
isotope, and it is not feasible to chelate a radioactive metal at the beginning stages of a 
long and arduous synthetic process. The metal would begin decaying from the time of 
its initial chelating and would no longer be useful as a PET imaging agent by the time 
the TMIA had been fully synthesized.  
Fortunately, our group has developed a workaround for this issue: the use of a 
placeholder metal. Metals of similar size to Cu2+ are useful as placeholders within the 
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DOTA group. That is, the placeholder metal is chelated in to the DOTA macrocycle in 
the early stages of synthesis, and functions as the protecting group until the end stages 
of synthesis. Then, the placeholder metal is displaced in an aqueous acidic solution, and 
the desired metal (i.e. Cu2+) is introduced and takes its own place in the DOTA group. 
Because the placeholder metal must be removed from the DOTA without 
destroying the rest of the TMIA, it is important to ensure that the metal is not too 
securely chelated – but it must also be stable enough to remain in place during the 
synthesis of a TMIA. Our hypothesis for this work was based on ionic radius: smaller 
metals, such as Gd and Cu, were expected to chelate strongly with the DOTA group, 
while larger metals would be less stable within that group. Due to the lanthanide 
contraction phenomenon, such as La3+ or Ce3+ are large enough to be significantly less 
stable within DOTA than smaller metals such as Gd3+ or Cu2+. Our aim was to find mild 
acidic conditions to displace the larger lanthanides without affecting the smaller ions 
(such as Gd3+).  We found several early literature studies which supported our 
hypothesis that mild acid would displace metals on the left of the lanthanide row more 
easily than those towards the right. 59–61 
After conducting kinetic studies of our own, we settled on La3+ as a favorite. 
The La-DOTA group holds up well to the further reactions necessary for TMIA 
synthesis, but La3+ is also readily displaced from the DOTA group in a solution of about 
0.1M TFA. Additionally, Gd3+ is strongly chelated by DOTA and is not displaced from 
the chelator under those conditions, making this suitable for use in di-metal TMIA 
synthesis (Figure 12). 
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Figure 12. Graph showing the displacement of La3+ by Cu2+ in a DOTA chelator in 0.1M TFA over 
several days, as well as the stability of Gd-DOTA in those same conditions. Data points were obtained 
by HPLC-UV analysis, and the intensity was taken from the area under the curve for the UV-
absorption of each compound. 
 
2.3 Evaluation and Analysis of Compounds 
Purified products are characterized by HMRS for an exact mass, and by NMR 
experiments for further confirmation of structure. T1 relaxation experiments are run on 
a 43MHz NMR spectrometer used to determine the relaxivity of the targeted contrast 
agents for use in MRI. These values can then be approximately compared to 
commercial MRI CAs, such as Gd-DOTA (trademarked as Dotarem). 
Unfortunately, we have no means here in our lab of testing our compounds in-
vivo as PET or MR contrast agents, so any testing on that front requires future 
collaborative efforts at another site. 
We are able, however, to verify the ability of a metal-containing TMIA to target 
a specific type of cell through CFM, through the addition of a fluorescent NIR dye 
imaging module to the TMIA, yielding a dual-modal TMIA.  In a previous dye-based 
project in our lab, we developed a TMIA containing both and MRI module and an NIRF 
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dye, Cy5.5, that effectively utilized c(RGDyK) as a targeting moiety. This TMIA was 
shown to selectively target the cells of interest, as evidenced by our collaborative work 
with Dr. Irene Evans’s lab at RIT, and their CFM imaging of A249 lung cancer cells 
treated with that TMIA (Figure 13). 
 
 
Figure 13. CFM image of A249 lung cancer cells treated with NucBlue and a previously synthesized 
TMIA for MRI and fluorescence of cancer cells, using the c(RGDyK) targeting peptide. Cell nuclei are 
stained blue; the TMIA appears red due to fluorescence. 
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Chapter 3. Results and Discussion 
3.1 Optimization of One-Pot Reactions for Synthesis of Imaging Modules 
In our group’s initial approaches to the DOTA-chelating imaging modules, a 
multi-step synthesis was developed (Scheme 3). However, the commercial DOTA-
OtBu3 used here was expensive, and the yields were not sufficient to justify the cost of 
the starting materials. Therefore, it was crucial to develop a more economical and 
efficient method of synthesizing these modules.  
 
1
2 3a
Gd(OAc)3
TFA
DCM/DMF
TBTU
DIPA
DMF 
 
 
 
To this end, a one-pot reaction was developed in our lab by former students 
(Scheme 4). In this method, the commercial unprotected DOTA was coupled to the 
Scheme 3. Multi-step procedure for synthesis of Fmoc-Lys(DOTA-Gd)-NH2 , 3a. 
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lysine side chain. However, the yield from this procedure was lower than expected. 
Therefore, one of the early goals for this project was to improve the yields of the one-
pot reaction. 
 
3b
1. TSTU
2. Fmoc-K(H)-NH2 
(shown)
3. Gd(OAc)3
DIPEA, DMF
 
 
After running both sets of reactions a number of times to synthesize the MRI 
contrast module, Fmoc-Lys(DOTA-Gd)-NH2 (3), (Scheme 3 & Scheme 4), we 
determined that any loss in overall yield in the one-pot method was outweighed by the 
reduced reaction & purification time investments required. The initial multistep 
synthesis requires at least three days to obtain the final product, whereas the more 
economical one-pot reaction can be run in a morning, and the purified product isolated 
that afternoon. 
While focusing efforts on the one-pot reaction, we found that certain 
modifications increased the yield of the reaction, and decreased the production of di-
and tri-substituted DOTA groups (Scheme 5). The use of a dilute reaction solution, 
heating the initial DOTA-OH in organic solution (to promote solvation), the slow 
Scheme 4. One-pot synthesis of Fmoc-Lys(DOTA-Gd)-NH2, 3b. 
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addition of the peptide coupling reagent TBTU (to favor mono-substitution on the 
DOTA), the slow addition of lysine, and allowing the reaction to run for no more than 
two or three hours all proved beneficial. 
(in excess)
di-substituted DOTA byproduct
tri-substituted DOTA byproduct
TSTU (excess)
 
 
Because the MRI and PET imaging modules are so similar, varying only in the 
metal used and the form of lysine used, the methods for synthesis are remarkably 
similar, as well. Improvements in method 3b also resulted in improvements for the 
synthesis of Fmoc-dLys(DOTA-La)-OH (5), shown in Scheme 6.  
Scheme 5. Undesirable di- and tri-substituted byproducts. 
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1. TSTU
2. Fmoc-dK(H)-OH 
(shown)
3. La(NO3)2
DIPEA, DMF
 
Scheme 6. One-pot synthesis of 5, PET placeholder module. 
 
 
3 4
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DEA 
 
 
3.2 Simple Fmoc Deprotections 
Removal of the Fmoc group exposes the primary amine of the peptide backbone 
for coupling chemistry in the next step. The Fmoc deprotection of 3 was simple enough 
(Scheme 7); treatment with diethylamine in organic solution provided reproducible 
results and yields of 90% and above. Initially, purification was done by liquid-liquid 
Scheme 7. Fmoc deprotection of 3 to yield H-Lys(DOTA-Gd)-NH2, 4. 
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extraction, with the H-K(DOTA-Gd)-NH2 product (4) found in the aqueous layer and 
the Fmoc byproduct taken up by the ethyl acetate organic layer. However, on small 
scale reactions of 20mg and below, we were concerned some product might be lost by 
this method, so we decided that triturating the crude product with ethyl acetate, 
centrifuging, and decanting the organic solvent was sufficient to remove the Fmoc 
byproduct. 
 
3.3 Troublesome Dimetal Peptide Coupling Reactions 
The truly troublesome reaction was the coupling of the two imaging modules to 
yield a di-metal imaging module. Initially, this reaction was run according to Scheme 
8. However, this resulted in disappointing yields.  The product was often not able to be 
isolated, nor did the reaction run to completion according to the HPLC-MS data 
acquired. 
A number of different reagents for were considered in an attempt to solve this 
problem (Figure 14). The use of different organic bases or peptide coupling reagents as 
found in the literature failed to provide different or improved results.  
After numerous failed attempts, we began to experiment with a readily available 
commercial amino acid (Fmoc-dAla-OH, Figure 15) to couple to the MRI contrast 
module. This way, at least, large quantities of valuable imaging modules were not 
wasted when the reactions failed.  
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Scheme 8. Initial method for peptide coupling to yield dual-modal imaging agent. 
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TSTU
TBTU
HATU
diethylamine
(DEA)
diisopropylethylamine 
(DIPEA)
triethylamine
(TEA)
n-methylmorpholine
(NMM)
pivaloyl 
chloride
 
Figure 14. A selection of organic bases (top row) and peptide coupling reagents (lower two rows) 
which were considered. 
 
 
Figure 15. Fmoc-dAla-OH (left) and Fmoc-dLys(DOTA-La)-OH (5), right. 
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Pivalyl chloride presented itself as a possible solution. Coupling reactions using 
pivalyl chloride as the coupling agent yielded good product, and the reaction run to 
completion with the trial amino acids according to the data from the HPLC-MS. Upon 
replacing the Fmoc-dAla-OH with the PET imaging module, however, the results were 
significantly less impressive. 
 It was back to the drawing board again: we needed to more thoroughly 
investigate what the basics of the reaction were and which factors (reagent, solvent, 
time, temperature, phase of the moon) were the most important.  To test the activation 
of the acid module by activating agents such as TSTU, a method was developed in 
which butyl amine was used to quench a small aliquot for analysis.  HPLC-MS reveals 
formation of butyl amide product and the saturated four-carbon chain decreases the 
polarity of the quenched product to provide good separation to a slower moving peak 
by HPLC-MS analysis; see  
Scheme 10. Additionally, the reaction of an NHS ester with H2O forms a product which 
is identical to the starting material, so diluting the active ester reaction with pure water 
for HPLC analysis is useless. 
 By testing the product of this step with a dilute aqueous solution of butylamine 
on HPLC-MS, it was evident that this step was never an issue with any set of reaction 
conditions used.   
Rather, it was found that it was the second step in the reaction – the addition of 
the MRI contrast module – which was so difficult to achieve. What remained was to 
determine which factor was negatively affecting this step. Some byproducts were seen 
in the MS data, true, but not enough was known to say exactly what these byproducts 
were (or how to avoid them). Alkaline, anhydrous conditions were needed, but 
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obtaining the correct pH by the addition of organic base was never an issue. The only 
remaining factor to consider was the choice of organic solvent. 
 
 
 
Scheme 9. Activation of an acidic lysine backbone by TSTU yields a succinimidyl leaving group. 
 
 
Scheme 10. Monitoring NHS ester formation by addition of butyl amine to form a more lipophilic 
product which is easily observed by HPLC-MS. 
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The true issue with the reaction proved to be solubility. After removal of the 
Fmoc protecting group, the MRI contrast module simply is not soluble in more 
commonly used solvents, such as NMP, DMF, ACN, or MeOH. In the past, we had 
simply heated the solution to 50℃ and given it time, in the hopes that the reagents 
would prove ‘soluble enough’ for what was needed. This, however, was not good 
enough. After running some solubility tests for the MRI contrast module, we discovered 
that the compound was readily soluble in DMSO. When the solvent was changed to 
DMSO, this allowed for successful and reproducible results of the coupling reaction. 
In addition to the reaction conditions required, the manner of purification was 
found to be an important factor to consider.  We use two primary methods of 
purification for the di-metal imaging modules: SPE and HPLC-prep, both utilizing 
reverse-phase stationary phases. We found that, although HPLC-prep is capable of 
providing sharper separations by use of a linear gradient and high pressure, yields were 
significantly smaller than expected. Conversely, when manual SPE methods were used, 
yields were in the range of what was expected based on data acquired while monitoring 
the reaction. We suspect this may be due to some chemistry occurring between the 
crude products and the HLPC columns used, but further work would be required to 
confirm or refute this. 
3.4 Fmoc Deprotection of dipeptide module 
 Upon successful coupling of the two amino acids, it was necessary to remove 
the Fmoc protecting group from the dipeptide to proceed with further chemistry. This 
reaction was run similarly to that discussed above for the deprotection of 3 to yield 4, 
and, likewise, provided reproducible results with high yields. 
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Scheme 11. Fmoc deprotection of 6 to yield H-dLys(DOTA-La)-Lys(DOTA-Gd)-NH2,7. 
 
3.5 SMCC vs DSS carbon linker 
 Within our modular approach, two different carbon-chain linkers are available 
for use. SMCC [succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, 
Figure 16] is often used for formation of peptide bonds and cross-linking in proteins. 
DSS [disuccinimidyl suberate, Figure 17] is used for a similar purpose and is more 
common in peptide synthesis and coupling as well. Because of the different functional 
groups, one may be more useful or efficient than the other for purposes of modular 
TMIA synthesis.  
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Figure 16. SMCC linker. 
 
Figure 17. DSS linker. 
 
 
 
 DSS is symmetrical and contains two succinimidyl groups which are 
equally reactive, while SMCC is asymmetrical and contains one succinimidyl group 
and one maleimide group. Therefore, SMCC is expected to be more selective for 
synthesis and limit the symmetric products formed. DSS, on the other hand, coupled to 
the targeting group in a timely manner, but the DSS reactions included additional 
factors for consideration, such as the water sensitivity of the succinimide group and the 
increased potential to form symmetric product. In the end, both DSS and SMCC were 
useful for the synthesis of TMIAs for MRI/PET of cancer, but DSS was preferable 
because it coupled more reliably than SMCC in the final steps. 
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3.6 Synthesis of TMIA containing SMCC linker 
 SMCC was the first of the two linkers to be introduced into the experimental 
procedures. The succinimide group coupled readily to the primary amine of lysine. 
However, the coupling of a primary amine to the maleimide of SMCC (which is 
intended for sulfur bonds) proved to be a difficult reaction to force to completion. 
SMCC was useful in that it did prevent symmetric products (wherein a dimetal imaging 
module is coupled to both the maleimide and the succinimidyl groups), but the final 
coupling to the targeting group took quite some time and/or heat to proceed; these 
reactions are shown in  
Scheme 12 and Scheme 13. Additionally, a method for the removal of excess 
SMCC from the crude product following  
Scheme 12 has yet to be developed, and the lack thereof introduces some 
complications in the coupling of c(RGDyK) to 9. 
.  
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Scheme 12. Coupling of SMCC to 7 for formation of 9. 
9
11
NMM
DMSO
 
Scheme 13. Coupling of c(RGDyK) to 9 for formation of 11. 
41 
 
 
3.7 Synthesis of TMIA containing DSS linker 
The final couplings, both of DSS to 7 ( 
Scheme 14) and of c(RGDyK) to 8 (Scheme 15), were improved by carefully 
determining the equivalents of each reagent to use, and by the use of a syringe pump. 
Formation of symmetrical product was reduced by ensuring an excess of DSS in 
solution. However, upon addition of a targeting group to the solution, the presence of 
excess DSS results in formation of compounds such as c(RGDyK)-DSS-c(RGDyK) 
rather than the desired c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2. Because 
c(RGDyK) is a rather expensive peptide to purchase, it is not practical to use overly 
excessive amounts to counter this problem. Therefore, 1 equivalent of DSS, 0.9 
equivalents of dimetal puzzle piece, and 1.2 equivalents of the targeting group were 
determined to be optimal for the final coupling reaction.  
 
7 8DSS
DEA, DMSO
 
Scheme 14. Coupling of DSS to di-metal module 7 for formation of 8. 
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Scheme 15. Coupling of c(RGDyK) to 8 for formation of 10. 
 
14
 
Figure 18. DCL-DSS-K(DOTA-Gd)-NH2 
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3.8 Convergent Synthesis of TMIA for MRI of Prostate Cancer 
One of the other major considerations was the order of coupling steps: that is, 
should we continue in the traditional linear right-to-left method of synthesizing 
peptides, or would a convergent synthetic method prove more efficient? (Scheme 1 
versus Scheme 2, page 21). The application of such a convergent method of synthesis 
was prompted by the use of a similar method for the synthesis of DCL-DSS-K(DOTA-
Gd)-NH2 (14), a targeted MRI contrast agent for PrCa.  
During work towards the synthesis of 14, we found that the most troublesome 
step of the synthesis was the final coupling of the DCL urea to the DSS linker. While 
small amounts of TCA were able to be synthesized this way, the reaction took a 
considerable amount of time to complete, and was not achieved on any scale suitable 
for further testing of the TCA. Therefore, we determined that the reaction could be 
simplified by coupling DSS to DCL first, and then coupling this component to the MRI 
contrast module ( 
Scheme 16). As of this writing, a manuscript from our group detailing the 
synthesis of 14 by this method is out for submission. 
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TEA
 
Scheme 16. Convergent synthesis of TMIA for MRI of prostate cancer,  
DCL-DSS-K(DOTA-Gd)-NH2 (14) 
 
Because a convergent method proved successful for that synthesis described 
above, we wondered whether it might also prove useful for the synthesis of a dual-
modal PET/MRI TMIA. Further support for a convergent synthesis is found in the 
potential for a method of purifying c(RGDyK)-DSS prior to the addition of an imaging 
moiety.  We have found that, though the succinimide group is reactive with water, this 
reactivity is reduced in acidic conditions, and, as found in the synthesis of 14, the 
targeting module DCL-DSS could be successfully purified by preparative HPLC. 
Because the lanthanide placeholder is, by design, labile in acidic aqueous conditions, 
purification of 8 by preparative HPLC with acidic buffers is not suitable. If a convergent 
synthesis were utilized, c(RGDyK)-DSS would not be subject to those same constraints 
and would therefore be a preferred intermediate.  
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There are drawbacks to a convergent method of synthesis, however. Because 
we want to emphasize the practicality of applying our methods of synthesis to any of a 
number of targeting groups, it is desirable to maintain linear methods of synthesis, 
wherein the targeting moiety is coupled to the linker in the last step of synthesis. 
Additionally, the primary difficulty in the DCL-linker coupling described above were 
due to the three acids present on the targeting moiety; c(RGDyK) is much less reactive 
in that regard, and therefore does not suffer quite the same difficulty in coupling. As of 
this writing, convergent methods of synthesis have not been studied for this TMIA, but 
will be considered in the future for efforts to improve synthetic methods. 
 
3.9 T1 Relaxivity Measurements 
 Once an MRI T1-contrast agent was developed, synthesized, and purified, its 
efficacy as an actual contrast agent had to be determined. This was done through 
measurement of T1 relaxivity on a 43MHz NMR from Magritek. These experiments 
allowed us to measure the effects of the contrast agent on the rate of relaxation of water 
within a magnetic field.  
 Small samples of the contrast agents were weighed, and serial dilutions were 
used to make solutions of 0, 0.5, 1, 2, 3, and 4 mM concentrations of Gd. These were 
run in the NMR in melting point capillary tubes (1.6 x 90 mm), held in a standard 5mm 
NMR tube with an adapter. The samples were exposed to a standard inversion-recovery 
pulse sequence, and the time between pulses was varied. When this integration of the 
signal was plotted against time between pulses, a logarithmic relationship was seen. 
Based on equations governing relaxivity, a time constant (T1) for each solution and the 
relaxivity (r1) of each compound could be determined.  
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 Because Gd(III) is a T1 contrast agent – that is, it primarily affects the T1 
relaxation processes of a sample, and not the T2 processes – we were interested only in 
the T1 relaxation times. The T1 relaxation time for a sample is related to its signal in 
MRI by equation (2); S is the observed signal, S0 is the maximum signal observed, t is 
the time between the initial RF-pulse and the measurement, or the interval time, and T1 
is the relaxation time of interest. We graph the signal (S) as the area under curve against 
the interval time (t), and obtain a logarithmic function (Figure 19). SOLVER is then 
used to fit equation (2) to the data by solving for values of S0 and T1. 
𝑆 = 𝑆0(1 − 𝑒
−
𝑡
𝑇1)   (2) 
 The reported relaxivity is the change in T1 as a function of the change in 
concentration of contrast agent (equation 1) – in this case, it is obtained by plotting the 
values of 1/T1 (or the R1 values) observed for a range of [Gd
3+] values and calculating 
the slope of that linear relationship (Figure 20). The cumulative data from DOTA-Gd 
(commercially available as Dotarem) and three Gd-containing compounds synthesized 
in our lab (3, 6, and 14) are shown below in Figure 21. 
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Figure 19. Sample plot used to determine T1 and S0 for a sample. Signal Intensity is obtained from the 
integration of the peak for each repetition, and the inversion time is increased for each repetition. The 
purple points represent the experimentally obtained data points, and the black curve represents the 
theoretical values obtained by equation (2). 
 
 
 
Figure 20. Sample plot used to determine the relaxivity of a contrast agent. R1 values are taken from 
the solution found for each equation (2) at each concentration. Y-intercept of the linear intercept 
represents the R1 for a sample of H2O without the presence of [Gd3+] contrast agent; the slope yields 
the relaxivity of the contrast agent at a given field strength. 
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Figure 21. Showing the relaxivities of four distinct compounds as measured by inversion-recovery 
sequences on the 43MHz Magritek NMR. 
 
3.10 Transmetallation of La3+ to Cu2+ Successful, Though Incomplete 
The final transmetallation process is arguably the most important step in this 
synthesis. It is the step which renders the TMIA useful for PET imaging, and it is the 
step which proves the usefulness of our method of using a placeholder metal in the 
chelating group against than using the more frequently used protecting groups in 
imaging agent synthesis. 
A few things were important to keep in mind for this transmetallation procedure. 
First, we know (thanks to J. Perez’s data) that La is labile in dilute (0.05 to 0.1 M) 
aqueous TFA solutions, and that Gd is also labile at higher concentrations of TFA (0.5 
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M). Therefore, it was important to use an appropriately dilute solution of TFA such that 
the La-DOTA bonds could be displaced, but that the stronger Gd-DOTA coordination 
bonds would not be disrupted.  
Additionally, it was important that the transmetallation occur relatively quickly. 
The half-life of 64Cu is approximately 12.7 hours; if it takes that long for 64Cu to replace 
57La in acidic solution, then the copper will hardly be useful for imaging by the end of 
the process and isolation of the product/TMIA. However, this is only an issue if the 
transmetallation is done in one step. If the process is completed in two steps, with the 
lanthanide being displaced overnight followed by the addition of Cu2+ to the solution 
the next day, this problem resolves itself. 
Based on previous data and results from transmetallation experiments, the 
demetallation of the final TMIA – the displacement of La3+ – was expected to take 
perhaps a weekend in solution. We found, however, that La3+ was completely replaced 
by Cu2+ (in the form of [Cu(NO3)2∙6H2O]) in 0.1M TFA aqueous solution overnight.  
As of the time of this writing, the experiments for the transmetallation of a final 
TMIA are not finished. In the two completed trials for the transmetallation processes 
of both 10 to 12 and 11 to 13, the process was expected to take several days, but HPLC-
MS analysis after twelve hours showed full conversion to product. In a future repetition 
of this experiment, the samples will be monitored much more frequently, and the effects 
of variables such as temperature and concentrations of reagents would be considered, 
as well. Additionally, we will pursue transmetallation in two steps as described above, 
in order to avoid the potential for a radioactive sample of copper to decay significantly 
during the process. 
Also not yet complete is a method to purify the final TMIA after 
transmetallation. An HPLC column purification is expected to be the most useful to 
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remove the excess Cu(NO3)2 and La from the sample, but with such small reaction 
scales as have been run thus far, a reverse-phase purification has not been successful. 
SPE methods have been successful for similar purifications following transmetallations 
of analogous compounds previously developed in our lab, and are expected to be useful 
here as well.  
 
3.11 Preferred Methods of Purification and Analysis 
As in any synthesis, purifying the product and isolating a pure sample is one of 
the crucial steps. Without purification, a product cannot properly be characterized. For 
these purifications, we focused on reverse phase (RP) chromatographic methods, 
including RP-HPLC and SPE. RP-HPLC and related methods were the most efficient 
method of purification for the compounds involved in this project due to their 
hydrophilic nature – they are much too polar for purification by normal phase column 
chromatography, and crystallization doesn’t provide sufficient separation of product 
from undesirable byproducts or excess reagent.  
Only those intermediates containing the Fmoc protecting group were suitable 
for analysis by UV detection during HPLC, due to the characteristic absorption of Fmoc 
at 264nm.   In general, the compounds in this synthesis were assayed and characterized 
by mass spectroscopy methods that included LC-MS and flow injection-MS (also called 
loop injection) methods.   
Historically, within our group, ACN/AmAc buffer systems were used for 
analysis of imaging agents and intermediates by HPLC-MS, and in most cases these 
were easily transferred to HPLC prep or SPE on C-18 cartridges with ACN/H2O 
systems. The reaction products involved here are, in most cases, significantly more 
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polar than any starting materials or byproducts, and this solvent system generally 
proved to be suitable for purification. However, towards the final stages of synthesis, 
this was no longer the case. 
The deprotected di-lysine, H-dK(DOTA-La)-K(DOTA-Gd)-NH2 (7), for 
example, proved difficult to purify, because all compounds of interest in the reaction 
were water-soluble and were so polar as to hardly be retained on a C18-based HPLC 
column. This problem was resolved by incorporation of a dilute acidic aqueous phase, 
and separation with a solvent system of ACN/TFA (aq.) was successful. By protonating 
the acidic nuclei, the polarity was reduced, and the purification was achievable with 
good results. Similar problems and solutions were encountered for the penultimate 
compound, c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2 (11). The only caveat 
associated with the use of an acidic buffer in these cases is that the La-DOTA bonds 
are, as discussed previously, intentionally broken in acidic solution. Therefore, it is 
important to keep the acidic solution at concentrations safely below those used for 
transmetallation, as well as to isolate the products relatively quickly after fractionation, 
in order to reduce the risk of prematurely displacing the lanthanide. 
3.12 Successful Synthesis of Several TMIAs by a Modular Approach 
Over the course of this project, our modular approach to the synthesis of TMIAs 
for both single- and dual-modal imaging was proven to be useful. Two TMIAs (12 and 
13) featuring c(RGDyK) as a targeting moiety and two DOTA-metal groups were 
synthesized and observed by both HPLC-MS and HRMS,  although further work on a 
larger scale will be required before the relaxivities of those compounds can be 
measured.  
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The single modal TMIA for MRI of PrCa, compound 14, was successfully 
synthesized and isolated; the relaxivity of this compound was measured and found to 
be comparable to, if not better than, that of the commercially-available Dotarem. This 
work provided a facile method for the preparation of a copper-containing analogue to 
14, DCL-DSS-K(DOTA-Cu)-NH2, which would be useful as a metal-based radiotracer 
for PET of PrCa. 
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Chapter 4. Conclusion 
The usefulness and applicability of our group’s modular method for the 
synthesis of amino-acid-based TMIAs has been shown by the synthesis of two related 
TMIAs, one for PET-MRI of cancer, and one for MRI of prostate cancer. Furthermore, 
our method of utilizing a La as a placeholder metal to be later replaced by Cu for PET 
in the presence of Gd was demonstrated on a final TMIA, although these processes and 
purification methods have yet to be optimized.  
 One-pot syntheses were utilized for each lysine-based imaging module, and 
TMIAs were synthesized from these modular components. During synthesis, 
compounds were characterized by HPLC-MS, HRMS, and NMR. Those compounds 
useful for MRI were tested by NMR to determine their effectiveness as MRI T1 contrast 
agents, and our compounds were found to be comparable and even slightly better than 
current commercially available non-targeted Gd-based contrast agents.  
 The solubility of intermediates was the most critical factor in the modular 
synthesis of dual modal TMIAs. The use of a metal as a placeholder and protecting 
group for DOTA was proven to be useful and effective, and the La placeholder was 
easily displaced in dilute TFA and replaced with Cu. Methods for dual-modal imaging 
agent synthesis were optimized to provide consistent results.  
 Results from this work present an effective means of synthesizing a variety of 
dual-modal TMIAs for combined PET and MRI studies, which may utilize a broad 
range of targeting moieties. The method is also applicable to imaging agents containing 
dyes that may be designed for PAI, fluorescence or optical imaging, and photodynamic 
therapy. Additionally, future research in our lab will explore modifications to the MRI 
contrast modules for the development of high-relaxivity TMIAs for use in MRI.  
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Chapter 5. Experimental Procedures 
General Considerations 
Chemicals were purchased from VWR (Radnor, PA), Sigma Aldrich (St. Louis, 
MO), Alfa Aesar (Ward Hill, MA), TCI (Tokyo, Japan), and Acros Organics (Morris 
Plains, NY), and were used as received unless otherwise stated. All were HPLC or 
American Chemical Society grade. Amino acid starting materials were purchased from 
Bachem (Bubendorf, Switzerland), and Chem-Impex Int’l Inc. (Wood Dale, IL). 
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was purchased from 
Macrocyclics (Houston, TX).  
The HPLC-MS instrument used was a Waters 2695 Alliance HPLC with a 
Waters 2998 Diode Array Detector and a Waters 3100 SQ Mass Spectrometer.  HPLC 
columns used included an Agilent XDB C18 column (3 mm x 100 mm, 3µ) and a 
Waters XBridge C18 column (50 mm x 3 mm, 3µ).  Mass spectra were recorded at unit 
resolution with positive and negative switching mode at either 35 or 50 V cone voltages.  
HPLC methods utilized 0.5mL/min flow rates and solvent systems of ACN or MeOH 
with a 0.1M ammonium acetate aqueous phase. 
Preparative HPLC was carried out with a Waters 600E system controller, and 
Waters 600 multi-solvent delivery system using a 30 mL/min flow rate.  For SPE 
purification, Varian Mega Bond Elute C18 cartridges were utilized, of appropriate size 
for the scale of the reaction. Preparative HPLC methods utilized a column from 
Keystone Scientific, Inc. Hyperprep C18 BDS (250mm x 20 mm, 8µ). 
 Chromatographic gradients for preparative HPLC, and SPE are denoted as 
(X/Y:A-B), where X is the organic mobile phase and Y is the organic mobile phase, 
and A and B are the initial and final concentrations of X, respectively. In the case of 
SPE, 5% intervals were used.  
 High resolution mass spectra (HRMS) were obtained on a Waters Synapt G2Si 
(School of Chemical Sciences, University of Illinois at Urbana-Champaign) using the 
following parameters: Flow injection at flow rate of 0.1 ml/min, H2O/ACN/0.1% 
Formic Acid, positive and negative mode ESI, Cone voltage = 25, capillary voltage = 
3.0, ion source temperature = - 100°C, desolation temperature  = 180℃,  nebulizing gas 
(N2) flow = 200 L/h, cone gas (N2) flow =  5L/h. 
 
F-K(DOTA-OtBu3)-NH2 (1) Fmoc-Lys(H)-NH2 (467mg, 0.97mmol) was dissolved 
in a mixture of DCM:DMF (1:1, 4mL total volume). Into a separate flask containing 
DCM (5mL) was added DOTA-OtBu (500.mg, 0.87mmol), HOBt (26.2mg, 
0.19mmol), TBTU (373.7mg, 1.16mmol), and DIPEA (752.2mg, 5.82mmol). The two 
solutions were combined and stirred 1 hour under inert conditions. Solvent was 
removed by rotary evaporation and vacuum pump. The crude product was purified by 
liquid-liquid extraction with EtOAC and DI H2O; organic layer was rotary evaporated 
and dried briefly under high vacuum. MS (HR, ESI) calc. for C47H75N7O10 922.5654 
[M+H], found 922.5624 [M+H]. 
 
F-K(DOTA)-NH2 (2) Compound 1 (894mg, 0.969mmol) was dissolved in TFA 
(15mL) with the addition of 0.3mL H2O and stirred, loosely capped, for two hours. TFA 
was removed by diluting the reaction solution with hexanes, then removing both 
solvents by rotary evaporation, and repeating this process three times. Once dried under 
vaccum, this crude product was brought forth to the next reaction without further 
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purification. MS (HR, ESI) calc. for C37H50N7O10 752.36192 [M-H], found 752.36240 
[M-H]. 
 
F-K(DOTA-Gd)-NH2 (3, method A) Compound 2 (730.mg, 0.968mmol) was 
dissolved in DMF (10mL). Gadolinium (III) acetate (983.2mg, 2.42mmol) was added 
to the solution. The reaction stirred under ambient conditions 1 hour. Crude product 
was isolated by rotary evaporation. Pure product was obtained by SPE (ACN/H2O:10-
60). Yield: 414.9mg (47%).  
 
F-K(DOTA-Gd)-NH2 (3, method B) Commercially-available DOTA (500.0mg, 
0.813mmol) was stirred into suspension in a solution of NMM (1233.4mg, 1.22mmol) 
in anhydrous DMF (35mL). This solution was heated briefly to promote solvation, then 
allowed to cool back to room temperature. A solution of TSTU (489.6mg, 1.63mmol) 
in DMF (10mL) was added to the reaction flask over 30 minutes with the use of a 
syringe pump, followed by the addition of a solution of Fmoc-Lys(H)-NH2 (380.0mg, 
0.81mmol) in the same manner. Immediately following the dropwise addition of this 
reagent, Gd(OAc)3 (495.5mg, 1.22mmol) was added to the reaction flask as a 
crystalline salt. The reaction was stirred another ten minutes.  Crude product was 
precipitated from the solution by the addition of ethyl ether and isolated by decanting 
the organic solvent after centrifugation. Purification by SPE (ACN/H2O:10-60) yielded 
the desired product. Yield: 200.8mg (27%). MS (HR, ESI) calc. for C37H48GdN7O10Na 
931.26014 [M+Na], found 931.2566 [M+Na]. 
 
H-K(DOTA-Gd)-NH2 (4) Compound 3 (50.0mg, 0.055mmol) was dissolved in 
anhydrous DMF (7mL). DEA (80.5mg, 1.10mmol) was added to this solution. The 
reaction stirred under inert atmosphere one (1) hour. Crude product was precipitated by 
addition of ethyl ether to the reaction solution, and organic solvent was decanted after 
centrifugation. Pure product was isolated by liquid-liquid extraction with ethyl acetate 
and H2O, with product found in the aqueous layer. Yield: 35.8mg (95%). MS (HR, 
ESI) calc. for C22H37GdN7O8 685.19447 [M-H], found 685.19477 [M-H].   
 
F-dK(DOTA-La)-OH (5) Commercially-available DOTA (500.2mg, 0.98mmol) was 
stirred into suspension in a solution of NMM (1139.2mg, 11.3mmol) in anhydrous 
DMF (30mL). This solution was heated briefly to promote solvation, then allowed to 
cool back to room temperature. A solution of TSTU (452.1mg, 1.50mmol) in DMF 
(10mL) was added to the reaction flask over 30 minutes with the use of a syringe pump, 
followed by the addition of a solution of Fmoc-dLys(H)-OH (304.0mg, 0.75mmol) in 
the same manner. Immediately following the dropwise addition of this reagent, 
La(NO3) (650.2mg, 1.50mmol) was added to the reaction flask as a crystalline salt. The 
reaction was stirred another ten minutes.  Crude product was precipitated from the 
solution by the addition of ethyl ether and isolated by decanting the organic solvent 
after centrifugation. Purification by SPE (ACN/H2O 10-60) yielded the desired 
product. Yield: 200.0mg (30%). MS (HR, ESI) calc. for C37H48LaN6O11 891.24457 
[M+H], found 891.2431 [M+H].   
 
F-dK(DOTA-Gd)-OH (6) Commercially-available DOTA (478.6mg, 0.934mmol) 
was stirred into suspension in a solution of NMM (1180.7mg, 11.7mmol) in anhydrous 
DMF (30mL). This solution was heated briefly to promote solvation, then allowed to 
cool back to room temperature. A solution of TSTU (468.6mg, 1.56mmol) in DMF 
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(10mL) was added to the reaction flask over 30 minutes with the use of a syringe pump, 
followed by the addition of a solution of Fmoc-dLys(H)-OH (315.0mg, 0.778mmol) in 
the same manner. Immediately following the dropwise addition of this reagent, 
Gd(OAc)3 (650.2mg, 1.50mmol) was added to the reaction flask as a crystalline salt. 
The reaction was stirred another ten minutes.  Crude product was precipitated from the 
solution by the addition of ethyl ether and isolated by decanting the organic solvent 
after centrifugation. Purification by SPE (ACN/H2O 10-60) yielded the desired 
product. Yield: 205.5mg (27.8%). MS (HR, ESI) calc. for C37H48GdN6O11 910.26233 
[M+H], found 910.2621 [M+H].   
 
F-dK(DOTA-La)-K(DOTA-Gd)-NH2 (7) Compound 5 (35.0mg, 3.93x10-2mmol) 
was dissolved in NMP (3mL) and to this solution was added triethylamine (39.8mg, 
0.393mmol) and a solution of TSTU (118.3mg, 0.393mmol) in NMP (3mL). This 
reaction stirred under argon 1hr and was monitored by HPLC-MS after treating a 
sample with 0.1% aqueous butylamine. Upon completion of this portion of the reaction, 
crude intermediate product was precipitated by the addition of EtOAc and diethyl ether, 
and after centrifugation the organic layer was decanted and the crude solid dried briefly 
under argon. Compound (4) (44.5mg, 6.48x10-2mmol) was dissolved in 2mL DMSO. 
To this solution was added triethylamine (39.8mg, 0.393mmol), followed by the 
previously isolated crude product which had been reconstituted in NMP (3mL). This 
reaction ran 1hr. Crude product was precipitated by the addition of ethyl ether, and the 
organic layer was decanted after centrifugation. Pure product was obtained by 
preparatory HPLC (ACN/0.1% acetic acid aqueous, 30-60%). Fractions containing 
pure product were collected, concentrated by rotary evaporation, and freeze dried. 
Yield: 16.2mg, 26.5%.  MS (HR, ESI) calc. for C59H85GdLaN13O18 780.22212 
[M+2H/2], found 780.223 [M+2H/2].   
 
H-dK(DOTA-La)-K(DOTA-Gd)-NH2 (8) Compound 7 (16.2mg, 1.04x10-3mmol) 
was dissolved in DMF (2mL) followed by the addition of diethylamine (15.21mg, 
0.208mmol). Reaction ran 1hr. Crude product was precipitated by the addition of 
diethyl ether. This was centrifuged and the organic layer decanted; the crude solid was 
triturated with EtOAc to remove Fmoc byproduct, and was again centrifuged and the 
organic layer, decanted. Yield: 12.9mg (92.8%). MS (HR, ESI) calc. for 
C44H74GdLaN13O16 1337.36822 [M+H], found 1337.369 [M+H].   
 
DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2 (9) Commercial DSS (7.3mg, 1.98x10-2 
mmol) was dissolved in DMSO (2mL) and to this was added NMM (13.4mg, 
0.132mmol). Compound 8 (17.7mg, 1.32x10-2 mmol) was dissolved in DMSO (2mL) 
and was added to the first solution dropwise over 30 minutes with the use of a syringe 
pump. After the completion of this addition, the reaction stirred under argon an 
additional 30 minutes before a small aliquot was treated with butylamine and monitored 
by HPLC-MS. Crude product was isolated by precipitation with anhydrous diethyl ether 
and centrifugation with the organic solvent discarded. This crude product was dried 
under high vacuum and was not further purified before use in the next reaction. 
 
SMCC-dK(DOTA-La)-K(DOTA-Gd)-NH2 (10) Compound 8 (12.9mg, 9.56x10-
3mmol) was dissolved in DMSO (2mL). To this was added triethylamine (9.77mg, 
9.65x10-2mmol) and SMCC (16.0mg, 4.34x10-2mmol). Reaction ran under argon 2hr. 
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Crude product was precipitated by the addition of diethyl ether, and the organic layer 
was decanted after centrifugation and the solid was dried under argon. 
 
c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2 (11) Compound 9 (17.0mg, 
1.07x10-2mmol) was dissolved in DMSO (1mL). To this was added a solution of NMM 
(10.82mg, 0.107mmol) and commercial c(RGDyK) (13.3mg, 2.14x10-2mmol) in 
DMSO (1mL).  Reaction stirred under argon 1hr. Crude product was precipitated by 
the addition of diethyl ether, and organic solvent was decanted after centrifugation. The 
crude product was dried under argon and was not further purified before continuing. 
MS (HR, ESI) calculated for C79H124GdLaN22O26 1045.860141 m/z [M-2H/2], found 
1045.8607 m/z [M-2H/2]. 
 
c(RGDyK)-SMCC-dK(DOTA-La)-K(DOTA-Gd)-NH2 (12) Compound 8 (1.3mg, 
8.36x10-4 mmol) was dissolved in DMSO (1mL). To this was added a solution of NMM 
(0.57mg, 8.36x10-3 mmol) and commercial c(RGDyK) (0.85mg, 9.19x10-4 mmol) in 
DMSO (1mL).  Reaction stirred under argon 2 days. Crude product was precipitated by 
the addition of diethyl ether, and organic solvent was decanted after centrifugation. The 
crude product was dried under argon and was not further purified before continuing. 
MS (HR, ESI) calc. for C83H125GdLaN23O27 1086.37099 [M-2H/2], found 1086.3707 
[M-2H/2].  
 
c(RGDyK)-DSS-dK(DOTA-Cu)-K(DOTA-Gd)-NH2 (13) Compound 11 (20.0mg, 
1.26x10-2 mmol) was dissolved in aqueous TFA solution (0.1M, 2mL). To this solution 
was added Cu(NO3)2 (23.6mg, 0.126mmol). This reaction stirred 24 hours at ambient 
conditions. The solvent was removed by rotary evaporation. MS (HR, ESI) calc. for 
C79CuH127GdN22O26Na2 688.92081 [M+H+2Na/3], found 688.9243 [M+H+2Na/3].  
 
c(RGDyK)-SMCC-dK(DOTA-Cu)-K(DOTA-Gd)-NH2 (14) Compound 12 (2.0mg, 
9.19x10-4 mmol) was dissolved in aqueous TFA solution (0.1M, 2mL). To this solution 
was added Cu(NO3)2 (1.72mg, 9.19x10
-3mmol). This reaction stirred 24 hours at 
ambient conditions. The solvent was removed by rotary evaporation. MS (HR, ESI) 
calc. for C83CuH125GdN23O27Na2 1071.37238 [M-2H+2Na/2], found 1071.3698 [M-
2H+2Na/2].  
 
DSS-K(DOTA-Gd)-NH2 (15) Commercial DSS (10.7mg, 2.92x10-2 mmol) was 
dissolved in DMSO:DMF (1:1, 2mL) and to this was added NMM (29.5mg, 
0.292mmol). Compound 4 (20.0mg, 2.92x10-2 mmol) was dissolved in DMSO (2mL) 
and was added to the first solution dropwise over 30 minutes with the use of a syringe 
pump. After the completion of this addition, the reaction stirred under argon an 
additional 30 minutes before a small aliquot was treated with butylamine and monitored 
by HPLC-MS. Crude product was isolated by precipitation with anhydrous diethyl ether 
and centrifugation with the organic solvent discarded. This crude product was dried 
under high vacuum and was not further purified before use in the next reaction. 
 
DCL-DSS-K(DOTA-Gd)-NH2 (16a) Compound 15 (5.0mg, 5.32x10-3mmol) was 
dissolved in DMSO (1mL). To this solution was added NMM (34.4mg, 0.266mmol) 
and DCL urea (8.5mg, 2.66x10-2mmol). The reaction was stirred 3 hours in an oil bath 
at 35C and under argon gas. Crude product was isolated by precipitation with anhydrous 
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diethyl ether and centrifugation with the organic solvent discarded. This crude product 
was used to experiment with HPLC and SPE purification methods. 
 
DCL-DSS-K(DOTA-Gd)-NH2 (16b)  Compound 4 (35.9mg, 5.24x10-2mmol) was 
dissolved in DMSO (2mL). To this was added TEA (67.7mg, 0.524mmol) and a 
solution of DCL-DSS (30.0mg, 5.24x10-2mmol) in DMSO (0.7mL). The reaction was 
stirred under argon 1hr. Crude product was isolated by precipitation with diethyl ether 
and centrifugation, with the organic solvent discarded. Purification by preparative 
HPLC (ACN/0.1% TFA in H2O, 5-40%) yielded pure product. Yield: 16.8mg, 28%. 
MS (HR, ESI) calc. for C42H70GdN10O17 1144.41614, found 1144.4150.  
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Appendix I. HPLC-MS & HRMS Data 
Compound 1 Fmoc-Lys(DOTA-OtBu3)-NH2 
 
 
 
Extracted wavelength chromatogram of 265nm for crude reaction mixture 
 
 
 
 
 
UV-Vis absorption spectrum at 6.60min with characteristic peak at 263nm for Fmoc protecting group 
 
 
 
 
 
Extracted ion chromatogram (XIC) of 921.8 m/z 
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Mass spectrum at 6.60min, 921.8 m/z [M-H] 
 
 
 
 
 
 
HRMS spectrum of 1. 922.5624 m/z [M+H] 
  
m/z
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Compound 2 Fmoc-Lys(DOTA)-NH2 
 
 
 
 
 
Extracted wavelength chromatogram of 264nm for crude reaction mixture 
 
 
 
 
 
UV-Vis absorption spectrum at 1.93 min with characteristic peak at 263nm for Fmoc protecting group 
 
 
 
 
 
XIC of 752.6 m/z  
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Mass spectrum at 1.99 minutes. 752.6 m/z [M-H] 
 
 
 
 
 
HRMS of 2. 752.3624 m/z [M-H] 
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Compound 3a Fmoc-Lys(DOTA-Gd)-NH2 
 
 
 
 
 
Extracted wavelength chromatogram of 263 nm for crude reaction mixture 
 
 
 
 
 
UV-Vis absorption spectrum at 4.32 min with characteristic peak at 263nm for Fmoc protecting group 
 
 
 
 
 
XIC of mass range of 904.1 to 909.7 m/z  
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
A
U
0.0
1.0e-1
2.0e-1
3.0e-1
4.0e-1
5.0e-1
6.0e-1
16_07_12_KJ_F-K(DOTA-Gd)-NH2_chelation_4hr_full 3: Diode Array 
263.532
Range: 6.723e-1
4.33
1.15
5.43
nm
200 250 300 350 400 450 500 550 600 650 700 750
A
U
0.0
2.5e-1
5.0e-1
7.5e-1
1.0
1.25
16_07_12_KJ_F-K(DOTA-Gd)-NH2_chelation_4hr_full 260 (4.317) 3: Diode Array 
1.495206.53
263.53
298.53
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
16_07_12_KJ_F-K(DOTA-Gd)-NH2_chelation_4hr_full 1: Scan ES- 
904.148_909.65
1.78e7
4.22
69 
 
 
 
 
Mass spectrum at 4.21 minutes. 905.8 m/z [M-H] 
 
 
 
 
 
Expanded parent ion from spectrum above, demonstrating Gd isotope pattern 
 
  
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
16_07_12_KJ_F-K(DOTA-Gd)-NH2_chelation_4hr_full 122 (4.215) 1: Scan ES- 
2.83e6905.83
904.72
118.96 904.33
902.99
686.85
121.19
492.17
400.52
907.60
909.63
1391.10910.63
1390.14
967.15
1388.99969.80
1843.631392.29
1420.94 1724.35
1877.81
1888.48
m/z
850 860 870 880 890 900 910 920 930 940 950
%
0
100
16_07_12_KJ_F-K(DOTA-Gd)-NH2_chelation_4hr_full 122 (4.215) 1: Scan ES- 
2.83e6905.83
904.72
904.33
902.99
859.10849.27 868.05
875.38
907.60
909.63
910.63
911.55
918.43 935.86938.47 952.64
70 
 
 
Compound 3b Fmoc-Lys(DOTA-Gd)-NH2 
 
 
 
 
Extracted wavelength chromatogram of 263 nm for crude reaction mixture 
 
 
 
 
 
UV-Vis absorption spectrum at 3.70 min with characteristic peak at 263nm for Fmoc protecting group 
 
 
 
 
 
XIC of mass range of 905.3 to 909.7 m/z 
 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
A
U
0.0
2.0e-1
4.0e-1
6.0e-1
8.0e-1
18_02_21_KJ_[18-125]_F-K(DOTA-Gd)-NH4_onepot_check-c 3: Diode Array 
263.532
Range: 1.183
1.04
3.70
5.01
3.94
4.37
nm
200 250 300 350 400 450 500 550 600 650 700 750
A
U
0.0
5.0e-1
1.0
1.5
18_02_21_KJ_[18-125]_F-K(DOTA-Gd)-NH4_onepot_check-c 446 (3.708) 3: Diode Array 
1.737208.53
263.53
298.53
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_02_21_KJ_[18-125]_F-K(DOTA-Gd)-NH4_onepot_check-c 1: Scan ES- 
905.309_909.69
2.54e6
3.66
71 
 
 
 
 
Mass spectrum at 3.59 minutes. 907.4 m/z [M-H] 
 
 
 
 
 
Expanded parent ion from spectrum above, demonstrating Gd isotope pattern 
 
 
 
HRMS of 3b. 931.2566 m/z [M+Na] 
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
18_02_21_KJ_[18-125]_F-K(DOTA-Gd)-NH4_onepot_check-c 104 (3.586) 1: Scan ES- 
2.90e5907.40
906.33
905.60119.04
904.37
179.13
229.01 901.68758.11
344.31
909.40
910.32
1391.711046.49 1873.471636.72
m/z
870 880 890 900 910 920 930 940 950
%
0
100
18_02_21_KJ_[18-125]_F-K(DOTA-Gd)-NH4_onepot_check-c 104 (3.586) 1: Scan ES- 
2.90e5907.40
906.33
905.60
904.37
901.68
909.40
910.32
942.39910.86 937.20 945.15
72 
 
 
Compound 4 H-Lys(DOTA-Gd)-NH2 
 
 
 
 
 
UV-Vis absorption spectrum at 1.23 minutes, demonstrating the lack of characteristic Fmoc absorption  
 
 
 
 
 
XIC of mass range of 682.0 to 687.6 m/z 
 
 
 
 
Mass spectrum at 1.13 minutes, 685.4 m/z [M-H] 
nm
200 250 300 350 400 450 500 550 600 650 700 750
A
U
0.0
2.5e-2
5.0e-2
7.5e-2
1.0e-1
1.25e-1
1.5e-1
16_07_21_KJ_H-K(DOTA-Gd)-NH2_defmoc_2hr 149 (1.233) 3: Diode Array 
1.506e-1201.53
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
16_07_21_KJ_H-K(DOTA-Gd)-NH2_defmoc_2hr 1: Scan ES- 
682.07_687.63
6.17e5
1.13
0.99
5.40
5.01
4.844.21
6.095.47 7.807.70
7.21
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
16_07_21_KJ_H-K(DOTA-Gd)-NH2_defmoc_2hr 33 (1.126) 1: Scan ES- 
2.85e5119.14
141.08
685.38
540.18
376.09
458.07
541.14
687.41
688.37829.33
1374.161004.90 1653.46 1926.42
73 
 
 
 
 
Expanded parent ion from spectrum above, demonstrating Gd isotope pattern 
 
 
 
 
 
HRMS of 4. 687.2101 m/z [M+H] 
  
m/z
640 650 660 670 680 690 700 710 720
%
0
100
16_07_21_KJ_H-K(DOTA-Gd)-NH2_defmoc_2hr 33 (1.126) 1: Scan ES- 
8.13e4685.38
683.35
682.29
681.20
663.22637.92
642.07 649.53 674.25
687.41
688.37
689.52 723.62706.15 709.27
74 
 
 
Compound 5 Fmoc-dLys(DOTA-La)-OH 
 
 
 
 
 
Extracted wavelength chromatogram of 263nm for purified sample of 5 
 
 
 
 
 
UV-Vis absorption spectrum at 3.85 min with characteristic peak at 263nm for Fmoc protecting group 
 
 
 
 
 
XIC of 889.4 m/z 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
A
U
0.0
5.0e-1
1.0
1.5
17_06_22_KJ_H-cK(DOTA-La)-june 3: Diode Array 
262.532
Range: 2.417
3.77
nm
200 250 300 350 400 450 500 550 600 650 700 750
A
U
0.0
2.0e-1
4.0e-1
6.0e-1
8.0e-1
1.0
1.2
17_06_22_KJ_H-cK(DOTA-La)-june 232 (3.850) 3: Diode Array 
1.264208.53
263.53
298.53
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
17_06_22_KJ_H-cK(DOTA-La)-june 1: Scan ES- 
889.448
4.79e7
3.70
75 
 
 
 
 
Mass spectrum at 3.70 minutes, 889.6 m/z [M-H]. 
 
 
 
 
 
 
HRMS of 5. 891.2431 m/z [M+H] 
 
  
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
17_06_22_KJ_H-cK(DOTA-La)-june 107 (3.695) 1: Scan ES- 
2.69e7889.63
889.16
888.82
888.67
119.04
677.17363.35
1335.22
1334.65
1334.23
890.85
1333.73891.51
1780.38
1779.46
1336.22
1778.85
1484.99
1781.26
1781.84
76 
 
 
Compound 6 Fmoc-dLys(DOTA-Gd)-OH 
 
 
 
 
 
 
Extracted wavelength chromatogram for 266nm of crude reaction mixture 
 
 
 
 
UV-Vis absorption at 2.12 minutes with characteristic peak at 263nm for Fmoc protecting group 
 
 
 
 
 
XIC of mass range 905.6 to 911.8 m/z [M-H] 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
A
U
0.0
5.0e-2
1.0e-1
1.5e-1
2.0e-1
2.5e-1
3.0e-1
[20180713] DMS [026-19] F-K(DOTA-Gd)-OH 30-4 3: Diode Array 
266.532
Range: 3.312e-1
2.44
1.08
3.13
3.78
5.14
nm
200 250 300 350 400 450 500 550 600 650 700 750
A
U
0.0
2.0e-1
4.0e-1
6.0e-1
[20180713] DMS [026-19] F-K(DOTA-Gd)-OH 30-4 296 (2.458) 3: Diode Array 
8.911e-1206.53
263.53
298.53
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
[20180713] DMS [026-19] F-K(DOTA-Gd)-OH 30-4 1: Scan ES- 
904.691_910.93
3.78e6
2.45
2.27
2.13
2.52
2.653.04
3.18
3.42
3.63
4.18
77 
 
 
 
 
 
Mass spectrum at 2.00 minutes, 906.7 m/z [M-H] 
 
 
 
 
 
Expanded parent ion of mass spectrum above, demonstrating Gd isotope pattern 
 
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
[20180713] DMS [026-19] F-K(DOTA-Gd)-OH 30-4 71 (2.447) 1: Scan ES- 
7.57e5908.59
118.98
906.62
905.60
904.63
174.92
677.63454.40
910.61
911.64
1363.85912.53
1360.64
1817.16
1393.27 1813.59 1824.35
m/z
880 885 890 895 900 905 910 915 920 925 930 935 940
%
0
100
[20180713] DMS [026-19] F-K(DOTA-Gd)-OH 30-4 71 (2.447) 1: Scan ES- 
7.57e5908.59
906.62
905.60
904.63
902.35884.46 891.77
910.61
911.64
912.53
930.53
927.76
916.53 932.46
78 
 
 
 
 
HRMS of 6. 910.2621 m/z [M+H] 
 
  
79 
 
 
Compound 7 Fmoc-dLys(DOTA-La)-K(DOTA-Gd)-NH2 
 
 
 
 
 
Extracted wavelength chromatogram of 263nm for crude reaction mixture 
 
 
 
 
 
UV-Vis absorption spectrum at 3.35min with characteristic peak at 263nm for Fmoc protecting group 
 
 
 
 
 
 XIC of mass range 778.9 to 781.9 m/z  
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
A
U
0.0
1.0e-1
2.0e-1
3.0e-1
19_05_17_KJ_[24-028]_F-dK(DOTA-La)-K(DOTA-Gd)-NH2 3: Diode Array 
263.532
Range: 3.819e-1
3.35
1.12
3.92
4.15
nm
200 250 300 350 400 450 500 550 600 650 700 750
A
U
0.0
2.0e-1
4.0e-1
6.0e-1
19_05_17_KJ_[24-028]_F-dK(DOTA-La)-K(DOTA-Gd)-NH2 404 (3.358) 3: Diode Array 
9.618e-1206.53
263.53
298.53
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
19_05_17_KJ_[24-028]_F-dK(DOTA-La)-K(DOTA-Gd)-NH2 2: Scan ES+ 
778.969_781.91
1.09e7
3.29
80 
 
 
 
 
XIC of mass range 1558.0 to 1562.3 m/z  
 
 
 
 
 
Mass spectrum at 3.26 minutes, 779.7 m/z [M+2H/2], 1559.9 [M+H] 
 
 
 
 
 
Expanded half-mass ion from spectrum above demonstrating Gd + La isotope pattern 
 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
19_05_17_KJ_[24-028]_F-dK(DOTA-La)-K(DOTA-Gd)-NH2 2: Scan ES+ 
1558.012_1562.27
1.93e5
3.29
3.43
5.69
3.60 7.54 7.85
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
19_05_17_KJ_[24-028]_F-dK(DOTA-La)-K(DOTA-Gd)-NH2 95 (3.255) 2: Scan ES+ 
3.36e6779.74
778.92
100.09
179.16
515.05 778.32
781.68
782.63
891.61 1559.88
1040.35
1304.33 1868.63 1949.91
m/z
760 765 770 775 780 785 790 795 800 805
%
0
100
19_05_17_KJ_[24-028]_F-dK(DOTA-La)-K(DOTA-Gd)-NH2 95 (3.255) 2: Scan ES+ 
3.36e6779.74
778.92
778.32
771.92770.51762.41
781.68
782.63
785.35 790.38 799.03
792.67 801.62
807.61
81 
 
 
 
 
Expanded parent ion from spectrum above demonstrating Gd + La isotope pattern 
 
 
 
 
HRMS of 7. 780.2230 m/z [M+2H/2] 
 
  
m/z
1540 1550 1560 1570 1580 1590 1600
%
0
100
19_05_17_KJ_[24-028]_F-dK(DOTA-La)-K(DOTA-Gd)-NH2 95 (3.255) 2: Scan ES+ 
4.44e41559.88
1558.67
1557.88
1555.62
1561.97
1564.72
1582.021566.07
1572.52 1595.12
82 
 
 
Compound 8 H-dLys(DOTA-La)-K(DOTA-Gd)-NH2 
 
 
 
 
 
UV-Vis absorption spectrum at 1.25 minutes, demonstrating the lack of characteristic Fmoc absorption  
 
 
 
 
 
XIC of mass range 667.8 to 671.0 m/z 
 
 
 
 
 
Mass spectrum at 1.20 minutes, 669.4 m/z [M+2H/s], 1337.6 m/z [M+H] 
nm
200 250 300 350 400 450 500 550 600 650 700 750
A
U
0.0
5.0e-1
1.0
1.5
2.0
2.5
19_05_23_KJ_[24-030]_H-dK(DOTA-La)-K(DOTA-Gd)-NH2_2hr 151 (1.250) 3: Diode Array 
2.928209.53
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
19_05_23_KJ_[24-030]_H-dK(DOTA-La)-K(DOTA-Gd)-NH2_2hr 2: Scan ES+ 
667.769_671
5.26e6
1.10
1.51
1.61
1.75
m/z
600 700 800 900 1000 1100 1200 1300 1400
%
0
100
19_05_23_KJ_[24-030]_H-dK(DOTA-La)-K(DOTA-Gd)-NH2_2hr 35 (1.199) 2: Scan ES+ 
1.82e6669.37
668.56
667.89
660.20
670.76
680.29
687.57
891.32
692.62768.54
1337.59
1011.97
894.34 1122.53 1334.881151.88 1342.30
83 
 
 
 
 
Expanded parent ion from spectrum above, demonstrating Gd + La isotope pattern 
 
 
 
 
 
Expanded half-mass ion from spectrum above, demonstrating Gd + La isotope pattern 
 
 
m/z
1320 1325 1330 1335 1340 1345 1350
%
0
100
19_05_23_KJ_[24-030]_H-dK(DOTA-La)-K(DOTA-Gd)-NH2_2hr 35 (1.199) 2: Scan ES+ 
1.79e51337.59
1336.68
1335.78
1334.88
1321.27
1338.62
1339.89
1342.30 1347.15
1344.50
1350.79
m/z
620 630 640 650 660 670 680 690 700 710 720 730
%
0
100
19_05_23_KJ_[24-030]_H-dK(DOTA-La)-K(DOTA-Gd)-NH2_2hr 35 (1.199) 2: Scan ES+ 
1.82e6669.37
668.56
667.89
660.20619.26
632.43 650.94
670.76
680.29
679.27 687.57
690.61
706.33 718.52 728.85
84 
 
 
 
HRMS of 8. 1337.3690 m/z [M+H] 
 
  
85 
 
 
Compound 9 DSS-dLys(DOTA-La)-Lys(DOTA-Gd)-NH2 
 
 
 
 
XIC of mass range 1543.6 to 1550.1 m/z  
 
 
 
 
 
Mass spectrum at 3.73 minutes, 1546.0 m/z [M-H] of 9 after treatment with butylamine 
 
 
 
 
 
 
Expanded parent ion from mass spectrum above, demonstrating Gd + La isotope pattern 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_13_KJ_[18-153]_DSS-dK(La)-K(Gd)-NH2_coupling_1hr_buam 1: Scan ES- 
1543.641_1550.07
8.01e5
3.803.73
1.13
4.08
4.29
4.81
7.625.29
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
18_06_13_KJ_[18-153]_DSS-dK(La)-K(Gd)-NH2_coupling_1hr_buam 108 (3.732) 1: Scan ES- 
2.91e5118.89
803.54
802.46
119.23 772.97
345.92 513.56
1546.01
1544.52
804.15
1543.40
879.57 1087.46
1608.88
1609.07
1610.22 2015.55
m/z
1520 1530 1540 1550 1560 1570 1580 1590
%
0
100
18_06_13_KJ_[18-153]_DSS-dK(La)-K(Gd)-NH2_coupling_1hr_buam 108 (3.732) 1: Scan ES- 
1.40e51546.18
1545.16
1543.92
1543.17
1542.45
1523.13
1528.00
1547.69
1549.09
1550.21
1578.34
1574.211551.59 1571.32
1581.34 1588.74
86 
 
 
Compound 10 SMCC-dLys(DOTA-La)-K(DOTA-Gd)-NH2 
 
 
 
 
 
XIC of mass range 777.3 to 780.6 m/z 
 
 
 
 
 
Mass spectrum at 1.12 minutes, 778.3 [M+2H/2] 
 
 
  
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
19_05_24_KJ_[24-031]_SMCC-dK(DOTA-La)-K(DOTA-Gd)-NH2_2hr 2: Scan ES+ 
777.328_780.63
3.75e6
1.10
1.20
1.58
m/z
760 765 770 775 780 785 790 795 800 805 810 815 820
%
0
100
19_05_24_KJ_[24-031]_SMCC-dK(DOTA-La)-K(DOTA-Gd)-NH2_2hr 41 (1.405) 2: Scan ES+ 
6.75e5778.25
777.57
765.48 770.52
780.26
789.76
788.75
787.35
800.93
791.34
808.17 813.52 816.77823.80
87 
 
 
Compound 11 c(RGDyK)-DSS-K(DOTA-Gd)-NH2 
 
 
 
 
 
XIC of mass range 1044.4 to 1047.9 m/z  
 
 
 
  
 
XIC of mass range 1074.1 to 2078.8 m/z 
 
 
 
 
 
XIC of mass range 1103.9 to 1108.1 m/z 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_13_KJ_[18-154]_c(RGDyK)-DSS-dK(La)-K(Gd)-NH2_coupling_1hr_buam 1: Scan ES- 
1044.398_1047.97
1.83e6
2.99
1.69
0.99
1.97
3.06
3.20
3.30
3.51
3.69
4.28
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_13_KJ_[18-154]_c(RGDyK)-DSS-dK(La)-K(Gd)-NH2_coupling_1hr_buam 1: Scan ES- 
1074.059_1078.83
3.72e6
2.99
1.52
3.13
3.27
3.48
3.79
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_13_KJ_[18-154]_c(RGDyK)-DSS-dK(La)-K(Gd)-NH2_coupling_1hr_buam 1: Scan ES- 
1103.859_1108.1
1.23e6
3.062.99
1.59
1.03
1.73 2.33
3.37
3.44
3.79
4.04 7.747.634.42
88 
 
 
 
 
 
Mass spectrum at 2.99 minutes, 1045.7 m/z [M-2H/2] 
 
 
 
 
Expanded half mass and adduct ions from spectrum above, 1045.7 m/z [M-2H/2],  
1076.0 m/z [M-H+OAc-/2], 1105.7 m/z [M+2OAc-/2] 
 
 
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
18_06_13_KJ_[18-154]_c(RGDyK)-DSS-dK(La)-K(Gd)-NH2_coupling_1hr_buam 86 (2.990)
6.23e6118.93
178.91
221.00
1076.01
618.30262.97
617.61
712.09
1045.69 1077.81
1425.471116.42 1504.81
m/z
1040 1050 1060 1070 1080 1090 1100 1110
%
0
100
18_06_13_KJ_[18-154]_c(RGDyK)-DSS-dK(La)-K(Gd)-NH2_coupling_1hr_buam 86 (2.990)
9.33e51076.01
1075.06
1045.69
1044.85
1044.13
1046.65
1047.57
1074.15
1048.39
1066.411063.58
1076.99
1077.81
1105.67
1078.50 1104.79
1079.36 1087.33 1094.58
1107.52
1108.37
1112.58
89 
 
 
 
 
 
HRMS of 11, 1047.8730 m/z [M+2H/2] 
  
90 
 
 
Compound 12 c(RGDyK)-SMCC-dLys(DOTA-La)-Lys(DOTA-Gd)-NH2 
 
 
 
 
 
XIC of mass range 1085.1 to 1089.4 m/z  
 
 
 
 
 
XIC of mass range 1114.7 to 1119.7 m/z  
 
 
 
 
 
Mass spectrum at 3.03 minutes, 1086.9 m/z [M-2H/2], 1116.8 m/z [M-H+OAc-/2] 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_13_KJ_[18-152]_c(RGDyK)-SMCC-dK(La)-K(Gd)-NH2_coupling_24hr 1: Scan ES- 
1085.07_1089.35
2.68e5
3.00
2.551.06
0.05 2.271.26
3.10
3.45
7.86
3.62
3.76
4.14 4.38 7.72
7.445.08 5.56
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_13_KJ_[18-152]_c(RGDyK)-SMCC-dK(La)-K(Gd)-NH2_coupling_24hr 1: Scan ES- 
1114.66_1119.65
3.34e5
3.14
3.03
2.24
0.36 0.99
1.92
3.45
3.73
4.35
7.89
5.01 7.547.19
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
18_06_13_KJ_[18-152]_c(RGDyK)-SMCC-dK(La)-K(Gd)-NH2_coupling_24hr 88 (3.032)
2.17e5118.95
1116.79
1086.94
179.01
617.98
217.08529.72
1085.04
806.82
1117.62
1147.75 1553.78
1482.51 1616.75 1997.98
91 
 
 
 
 
Expanded half-mass ion from spectrum above 
 
 
 
 
 
HRMS of 12, 1086.3701 [M-2H/2], 1109.3734 [M-3H+Na/2],   
m/z
1070 1075 1080 1085 1090 1095 1100 1105
%
0
100
18_06_13_KJ_[18-152]_c(RGDyK)-SMCC-dK(La)-K(Gd)-NH2_coupling_24hr 88 (3.032)
5.38e41086.94
1085.78
1085.04
1084.00
1068.91 1077.21
1087.86
1089.63
1102.78
1100.06
1107.12
92 
 
 
Compound 13 c(RGDyK)-DSS-dLys(DOTA-Cu)-Lys(DOTA-Gd)-NH2 
 
 
XIC of mass range 1007.8 to 1011.3 m/z 
 
 
 
 
 
Mass spectrum at 2.96 minutes, 1009.1 m/z [M-2H/2] 
 
 
 
 
 
Expanded half-mass ion from spectrum above 
 
 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_14_KJ_[18-155]_c(RGDyK)-DSS-dK(Cu)-K(Gd)-NH2_transmetallation_1day 1: Scan ES- 
1007.762_1011.26
1.06e5
2.93
2.82
2.72
1.891.61
1.26
2.61
3.24
3.62
7.64
4.314.17
4.94 5.80
5.04 5.91
7.156.70 7.92
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
18_06_14_KJ_[18-155]_c(RGDyK)-DSS-dK(Cu)-K(Gd)-NH2_transmetallation_1day 86 (2.961)
1.88e5118.88
1009.11178.96
618.55
301.78377.47 1006.82711.75
1117.01
2018.941425.07 1751.94
m/z
995 1000 1005 1010 1015 1020
%
0
100
18_06_14_KJ_[18-155]_c(RGDyK)-DSS-dK(Cu)-K(Gd)-NH2_transmetallation_1day 86 (2.961)
2.44e41009.11
1008.23
1006.82
990.73 1006.051002.63999.03
1009.99
1010.90
1011.76
1020.84
1024.37
93 
 
 
Compound 14 c(RGDyK)-SMCC-dLys(DOTA-Cu)-Lys(DOTA-Gd)-NH2 
 
 
 
 
 
XIC of mass range 1047.2 to 1051.8 m/z 
 
 
 
 
 
XIC of mass range 1077.7 to 1082.1 m/z 
 
 
 
 
 
Mass spectrum at 3.24 minutes, 1048.3 m/z [M-2H/2], 1078.8 m/z [M-H+OAc-/2] 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_14_KJ_[18-156]_c(RGDyK)-SMCC-dK(Cu)-K(Gd)-NH2_transmetallation_1day F1
1047.219_1051.8
1.57e5
3.17
3.07
2.201.85
3.24
3.45
3.663.72
5.353.86
4.70
7.54
7.026.01
6.53
7.75
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_06_14_KJ_[18-156]_c(RGDyK)-SMCC-dK(Cu)-K(Gd)-NH2_transmetallation_1day F1
1077.75_1082.1
9.82e4
3.17
3.10
3.03
2.130.12
2.62
3.31
4.83
4.59
3.76
4.31
7.40
6.535.32 6.08
6.81
m/z
850 900 950 1000 1050 1100 1150 1200 1250 1300
%
0
100
18_06_14_KJ_[18-156]_c(RGDyK)-SMCC-dK(Cu)-K(Gd)-NH2_transmetallation_1day 94 (3.239)
1.52e41048.31
1047.42
1038.36
830.49
973.28946.85886.94
1049.92
1078.83
1080.01
1116.79
1158.44
1210.77 1271.86 1301.74
94 
 
 
 
 
Expanded half-mass ion from spectrum above 
 
 
 
 
 
HRMS of 14, 1071.3698 m/z [M+2Na/2] 
  
m/z
1035 1040 1045 1050 1055 1060 1065 1070
%
0
100
18_06_14_KJ_[18-156]_c(RGDyK)-SMCC-dK(Cu)-K(Gd)-NH2_transmetallation_1day 94 (3.239)
1.52e41048.31
1047.42
1038.36
1037.47
1046.22
1049.92
1050.71
1051.60
1055.79 1060.31
1067.19 1069.41
95 
 
 
Compound 15 DSS-Lys(DOTA-Gd)-NH2 
 
 
 
 
 
XIC of mass range 894.1 to 897.8 m/z  
 
 
 
 
 
Mass spectrum at 2.49 minutes, 895.7 m/z [M-H] of 15 after treatment with butylamine 
 
 
 
 
 
Expanded parent ion from spectrum above 
  
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_05_22_KJ_[18-141]_DSS-K(DOTA-Gd)-NH2_1hr 1: Scan ES- 
894.148_897.84
1.75e7
2.56
2.46
2.21
2.95 3.09
4.173.34
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000
%
0
100
18_05_22_KJ_[18-141]_DSS-K(DOTA-Gd)-NH2_1hr 72 (2.494) 1: Scan ES- 
7.46e6118.86
895.71
893.74
178.95
892.77
220.94
263.00 686.58515.16
898.78
899.75
1375.89
959.66 1239.77
1792.48
1534.53
1853.55
m/z
860 870 880 890 900 910 920 930 940 950 960 970 980
%
0
100
18_05_22_KJ_[18-141]_DSS-K(DOTA-Gd)-NH2_1hr 72 (2.494) 1: Scan ES- 
3.83e6895.71
894.69
893.74
892.77
891.81
857.62
877.25
896.69
898.78
899.75
954.72
925.72900.74
910.53
952.72932.63
958.77
959.66 981.47 985.17
96 
 
 
Compound 16a DCL-DSS-Lys(DOTA-Gd)-NH2 
 
 
 
 
XIC of mass range 568.9 to 572.6 m/z 
 
 
 
 
 
XIC of mass range 1140.1 to 1144.3 m/z 
 
 
 
 
Mass spectrum at 1.06 minutes, 570.5 m/z [M-2H/2], 1143.8 m/z [M-H] 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_05_23_KJ_[18-141]_DCL-DSS-K(DOTA-Gd)-NH2_overnight 1: Scan ES- 
568.949_572.6
1.89e6
1.02
0.81
1.09
1.31
1.48
5.59
1.79
2.07
4.862.67
5.73
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_05_23_KJ_[18-141]_DCL-DSS-K(DOTA-Gd)-NH2_overnight 1: Scan ES- 
1140.16_1144.25
4.34e5
1.06
0.92
0.74
1.13
1.58
2.04 2.28
2.77 4.583.54 4.16 5.875.735.34 6.04
m/z
600 700 800 900 1000 1100 1200
%
0
100
18_05_23_KJ_[18-141]_DCL-DSS-K(DOTA-Gd)-NH2_overnight 31 (1.059) 1: Scan ES- 
4.57e5570.54
569.62
568.94
532.27
571.83
636.54
572.64
774.64
658.63
1143.83839.50
1138.871059.45 1164.80
97 
 
 
 
 
 
 
 
Expanded half-mass ion from spectrum above 
 
 
 
 
 
Expanded parent ion from spectrum above 
 
  
m/z
550 555 560 565 570 575 580 585 590
%
0
100
18_05_23_KJ_[18-141]_DCL-DSS-K(DOTA-Gd)-NH2_overnight 31 (1.059) 1: Scan ES- 
4.57e5570.54
569.62
568.94
561.14557.07548.39555.20
562.90
571.83
572.64
581.99
580.44
582.73 589.20590.24
m/z
1120 1130 1140 1150 1160 1170
%
0
100
18_05_23_KJ_[18-141]_DCL-DSS-K(DOTA-Gd)-NH2_overnight 31 (1.059) 1: Scan ES- 
7.63e41143.83
1141.88
1139.81
1138.87
1127.16
1117.27
1129.27
1163.841144.82
1161.98
1146.02
1160.92
1151.30
1164.80
1165.82
1176.72
98 
 
 
Compound 16b DCL-DSS-Lys(DOTA-Gd)-NH2 
 
 
 
 
 
XIC of mass range 1140.2 to 1145.3 m/z 
 
 
 
 
 
XIC of mass range 569.0 to 572.7 m/z 
 
 
 
 
 
Mass spectrum at 1.09 minutes, 570.1 m/z [M-2H/2], 1142.8 m/z [M-2H/2]  
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_07_17_KJ_[24-006]_DCL-DSS-K(DOTA-Gd)-NH2_full_20 1: Scan ES- 
1140.262_1145.26
4.92e5
0.89
0.12
1.44
0.99
1.61
1.79
2.00
2.31
7.352.52 5.854.67
3.11
4.533.56 4.81 6.51 6.96
7.66
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
100
18_07_17_KJ_[24-006]_DCL-DSS-K(DOTA-Gd)-NH2_full_20 1: Scan ES- 
569.01_572.7
6.75e5
1.480.99
0.89
0.29
1.65
1.75
1.93
2.31
3.35
3.11
4.15
m/z
500 600 700 800 900 1000 1100 1200
%
0
100
18_07_17_KJ_[24-006]_DCL-DSS-K(DOTA-Gd)-NH2_full_20 32 (1.094) 1: Scan ES- 
1.52e5570.06
569.23
568.51
571.02
1142.79
571.96
1140.98
572.65
784.44
573.68
775.65
645.53 868.85 893.27
1139.21
1009.92
1144.28
1145.19
1145.761212.44
99 
 
 
 
 
 
 
Expanded parent ion from spectrum above 
 
 
 
 
 
Expanded half mass ion from spectrum above 
 
 
 
m/z
1120 1130 1140 1150 1160 1170 1180
%
0
100
18_07_17_KJ_[24-006]_DCL-DSS-K(DOTA-Gd)-NH2_full_20 32 (1.094) 1: Scan ES- 
7.94e41142.79
1140.98
1140.03
1139.21
1125.971122.24
1144.28
1145.19
1145.76
1180.411161.48
1153.80 1168.01
m/z
562 564 566 568 570 572 574 576 578 580
%
0
100
18_07_17_KJ_[24-006]_DCL-DSS-K(DOTA-Gd)-NH2_full_20 32 (1.094) 1: Scan ES- 
1.52e5570.06
569.23
568.51
561.86
565.91
571.02
571.96
572.65
573.68 577.44
574.91 578.38 579.93
100 
 
 
 
 
HRMS of 16b, 1144.4150 m/z [M+H] 
  
